Ispor 2018 Final Program

ISPOR2018
The Leading Global Conference for Health Economics and Outcomes Research
May 19-23, 2018

Baltimore Convention Center
Baltimore, MD, USA
Real-World Evidence,
Digital Health, and the
New Landscape for Health Decision Making
Program and Schedule of Events

#ISPORBaltimore
WI-FI NETWORK: ISPOR // PASSWORD: IQVIA2018
www.ispor.org
ISPOR2018
May 19-23, 2018
Baltimore, MD, USA
Table of Contents
ISPOR 2018 AGENDA AT A GLANCE 4
CONFERENCE PROGRAM COMMITTEE 7
EVENT SPONSORS 8
PLENARY SESSIONS 9
SCHEDULE OF EVENTS
● SATURDAY, MAY 19 12
● SUNDAY, MAY 20 15
● MONDAY, MAY 21 19
● TUESDAY, MAY 22 25
● WEDNESDAY, MAY 23 33
INVITATIONAL GROUP MEETINGS 37
POSTER OVERVIEW 40
EXHIBIT PROGRAM OVERVIEW 41
EXHIBITOR LISTING 42
EXHIBIT/POSTER HALL FLOOR PLAN 43
2018 ISPOR AWARDS PROGRAM 45
KEY INFORMATION 55
CONFERENCE ROOMS FLOOR PLAN 56
#ISPORBaltimore 3
ISPOR2018 May 19-23, 2018 | Baltimore, MD, USA
ISPOR 2018 Agenda at a Glance

Saturday, May 19, 2018
7:00AM-6:00PM REGISTRATION HELP DESK HOURS
8:00AM-5:00PM SHORT COURSE FULL DAY
8:00AM-12:00PM SHORT COURSE MORNING SESSION
1:00PM-5:00PM SHORT COURSE AFTERNOON SESSION
5:30PM-6:30PM EDUCATIONAL SYMPOSIUM
Sunday, May 20, 2018

8:00AM-10:00PM EXHIBITOR MOVE IN
8:00AM-12:00PM SHORT COURSE MORNING SESSION
12:00PM-6:00PM SPEAKER READY ROOM HOURS
1:00PM-5:00PM SHORT COURSE AFTERNOON SESSION
6:30PM-8:30PM ISPOR STUDENT RESEARCH COMPETITION
8:30PM-9:30PM ISPOR STUDENT & FACULTY ICEBREAKER RECEPTION
Monday, May 21, 2018

8:00AM-6:00PM SPEAKER READY ROOM HOURS
8:30AM-7:45PM EXHIBIT/POSTER HALL HOURS
8:30AM-2:00PM RESEARCH POSTER PRESENTATIONS - SESSION I
8:30AM-10:30AM WELCOME & FIRST PLENARY SESSION
10:30AM-11:00AM BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I
11:00AM-12:00PM BREAKOUT SESSION
11:00AM-12:00PM ISPOR NEW PROFESSIONAL EVENT - CAREER ADVICE ACROSS THE GLOBE
12:00PM-2:15PM LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I
12:30PM-1:30PM ISPOR STUDENT RESEARCH SHOWCASE
12:30PM-2:00PM ISPOR WOMEN IN HEALTH ECONOMICS AND OUTCOMES RESEARCH
1:00PM-2:00PM POSTER AUTHOR DISCUSSION HOUR - SESSION I
2:15PM-3:15PM SPOTLIGHT SESSION
3:15PM-3:45PM BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION II
3:30PM-7:30PM RESEARCH POSTER PRESENTATIONS - SESSION II
3:45PM-4:45PM BREAKOUT SESSION
6:00PM-7:45PM EXHIBITORS’ OPEN HOUSE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION II
6:00PM-7:00PM MEET THE WOMEN IN HEOR SPEAKERS RECEPTION
6:30PM-7:30PM POSTER AUTHOR DISCUSSION HOUR - SESSION II
7:30PM-9:00PM ISPOR GLOBAL NETWORKS RECEPTION
4 #ISPORBaltimore
Tuesday, May 22, 2018

7:15AM-8:15AM EDUCATIONAL SYMPOSIUM
7:30AM-8:30AM ISPOR PERSONALIZED/PRECISION MEDICINE SPECIAL INTEREST GROUP MEETING
8:30AM-2:00PM RESEARCH POSTER PRESENTATIONS - SESSION III
8:30AM-10:30AM WELCOME & SECOND PLENARY SESSION
10:30AM-11:00AM BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION III
12:00PM-2:15PM LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION III
12:30PM-12:45PM ISPOR GENERAL SPECIAL INTEREST GROUP MEETING
12:45PM-2:00PM ISPOR PATIENT-RESEARCH SPECIAL INTEREST GROUPS MEETING
12:45PM-2:00PM ISPOR BIOSIMILAR SPECIAL INTEREST GROUP MEETING
12:45PM-2:00PM ISPOR MEDICAL DEVICES AND DIAGNOSTICS SPECIAL INTEREST GROUP MEETING
12:45PM-2:00PM ISPOR NUTRITION ECONOMICS SPECIAL INTEREST GROUP MEETING
1:00PM-2:00PM POSTER AUTHOR DISCUSSION HOUR - SESSION III
1:15PM-2:00PM ISPOR GENERAL BUSINESS MEETING
3:15PM-3:45PM BREAK & EXHIBITS VIEWING
3:30PM-7:30PM RESEARCH POSTER PRESENTATIONS - SESSION IV
6:00PM-7:45PM EXHIBITORS’ WINE & CHEESE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION IV
6:30PM-7:30PM POSTER AUTHOR DISCUSSION HOUR - SESSION IV
9:00PM-11:00PM ISPOR SOCIAL EVENT
Wednesday, May 23, 2018

7:15AM-8:15AM EDUCATIONAL SYMPOSIUM
8:30AM-1:30PM RESEARCH POSTER PRESENTATIONS - SESSION V
8:30AM-9:30AM BREAKOUT SESSION
9:30AM-10:00AM BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION V
10:00AM-11:45AM WELCOME & THIRD PLENARY SESSION
11:45AM-1:45PM LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION V
12:30PM-1:30PM POSTER AUTHOR DISCUSSION HOUR - SESSION V
2:45PM-3:00PM BREAK
www.ispor.org 5
ISPOR 2018 Conferences
ISPOR Asia Pacific 2018
8-11 September 2018 / Tokyo, Japan
Moving Into Action: Informing Policy and Strengthening Healthcare Systems
in Asia Pacific
Register by 17 July for savings.
ISPOR Dubai 2018

19-20 September 2018 / Dubai, United Arab Emirates
Healthcare Decision-Making in the Middle East and North Africa: Role of
Health Economics, Outcomes Research and Health Technology Assessment
Register by 7 August for savings.
ISPOR Summit
October 19, 2018 / Washington, DC, USA
New Approaches to Value Assessment – Towards More Informed Pricing
in Healthcare
ISPOR Europe 2018

10-14 November 2018 / Barcelona, Spain
Abstract submission deadline: 13 June 2018
For more information and to register:

www.ispor.org
Upcoming Trainings
ISPOR HTA-USA Training Program ISPOR HTA Training Program
June 19-21, 2018 23-26 July 2018
Princeton, NJ, USA Lima, Peru
Looking ahead to 2019 Conferences:

ISPOR 2019 ISPOR Latin America 2019 ISPOR Europe 2019
May 18-22, 2019 12-14 September 2019 2-6 November 2019
New Orleans, LA, USA Bogotá, Colombia Copenhagen, Denmark
Abstract submissions open: Abstract submissions open: Abstract submissions open:
October 1, 2018 1 December 2018 1 March 2019
6 #ISPORBaltimore
Conference Program Committee

ISPOR thanks the Conference Program Committee for its contributions in developing
the scientific community’s leading HEOR program.
PROGRAM COMMITTEE CO-CHAIRS ISSUE PANEL REVIEW COMMITTEE CO-CHAIRS
C. Daniel Mullins, PhD Catherine Tak Piech, MBA

University of Maryland School Value Assessment Strategist,
of Pharmacy, New Providence, NJ, USA
Baltimore, MD, USA
Rachael L. Fleurence, PhD Lotte Steuten, PhD

National Evaluation System Fred Hutchinson Cancer
for Health Technology Research Center and
Coordinating Center, University of Washington,
Medical Device Innovation Seattle, WA, USA
Consortium,
Arlington, VA, USA
Kathryn M. O’Callaghan,
BSE, BA
U.S. Food and Drug
Administration (FDA),
RESEARCH REVIEW COMMITTEE CO-CHAIRS Silver Spring, MD, USA
Ebere Onukwugha, MS, PhD

University of Maryland School
of Pharmacy,
Baltimore, MD, USA WORKSHOP REVIEW COMMITTEE CO-CHAIRS
Marc Berger, PhD

Jan B. Pietzsch, PhD Consultant,
Wing Tech Inc., New York, NY, USA
Irvine, CA, USA
David Vanness, PhD

University of Wisconsin,
Brian Seal, PhD, RPh, MBA
Madison, WI, USA
AstraZeneca,
Gaithersburg, MD, USA
K. Jack Ishak, PhD

Ya-Chen Tina Shih, PhD Evidera,
University of Texas MD Montreal QC,
Anderson Cancer Center, Canada
Houston, TX, USA
www.ispor.org 7
Thank You to Our Sponsors
Platinum Level Sponsors
Gold Level Sponsors
Silver Level Sponsors
Bronze Level Sponsors
8 #ISPORBaltimore
Plenary Sessions
FIRST PLENARY SESSION: INFLECTION POINT FOR REAL-WORLD EVIDENCE? THE

TRANSFORMATIONAL ROLE OF DIGITAL HEALTH
In the last 10 years, we have witnessed an exponential increase in the generation of digital health data from
electronic health records (EHRs), claims, billing and patient- and device-generated data. At the same time, it’s being
Fleurence Hernandez increasingly recognized that traditional clinical trials are expensive, lengthy, and do not adequately study the patient’s
specific characteristics and treatment preferences. The promises of real-world evidence—lower cost; higher quality
(including retaining randomization); near real time; regulatory, coverage, and clinical support; and patient decision
making—are being addressed in a number of transformational and innovative programs. Are we finally at the
inflection point to deliver on the promises of real-world evidence and digital health? The panel is composed of a
number of leaders who have been working in this area on cutting-edge initiatives and will be interviewed on what
McMurry- Marinac- they have learned to date, current barriers to the use of real-world evidence, and what the future holds both within
Heath Dabic and outside of the United States.
Moderator: Rachael L. Fleurence, PhD, National Evaluation System for Health Technology Coordinating Center,
Medical Device Innovation Consortium, Arlington, VA, USA
Speakers: Adrian F. Hernandez, MD, MHS, Duke University School of Medicine, Durham, NC, USA; Michelle
McMurry-Heath, MD, PhD, Johnson & Johnson Medical Device Companies, Washington, DC, USA; Danica Marinac-
Dabic, MD, PhD, MMSc, FISPE, U.S. Food & Drug Administration, Silver Spring, MD, USA; Sally Okun, RN, MMHS,
Okun PatientsLikeMe, Cambridge, MA, USA
SECOND PLENARY SESSION: DIGITAL HEALTH — HELP OR HYPE?

The use of digital technologies, such as smart phones, social media platforms, and wearables increases in
participation in both health-related research and general tracking of health metrics. This session will provide a
balanced overview of where there is reliable evidence that digital technologies have improved health and where
Mullins Jones there is mainly hype. The session will address the following questions:
• Does the empirical evidence confirm that digital health has actually improved public health?
• What evidence is there regarding the global impact of digital health on research?
• Has digital health helped to close health disparities’ gaps?
• What are ethical concerns surrounding tracking health data and how are they being managed?
Moderator: C. Daniel Mullins, PhD, University of Maryland School of Pharmacy, Baltimore, MD, USA
Mark Sam-Agudu Speakers: Chris A. Jones, DPhil, MSc, FRSM, Arizona State University, Tempe, AZ, USA, trUStr.US, and University
of Vermont Health Network, Burlington, VT, USA; Ejim E. Mark, MD, MPH, MBA, Access Healthcare Foundation,
Rockville, MD, USA; Nadia A. Sam-Agudu, MD, University of Maryland School of Medicine, and
Institute of Human Virology Nigeria, Abuja, Nigeria
THIRD PLENARY SESSION: EXAMINING THE ROLE OF PATIENT PREFERENCES TO INFORM

REGULATORY DECISIONS
The US Food and Drug Administration (FDA) user fee agreements (MDUFA IV and PDUFA VI) require the FDA to
develop systematic approaches to develop fit-for-purpose tools to collect meaningful patient input that can be
Reed Levitan incorporated into regulatory review. The Center for Drug Evaluation and Research (CDER) and the Center for
Devices and Radiological Health (CDRH) have taken different but complementary approaches to incorporate views.
CDRH has understand quantitative preference elicitation methods to ascertain patients’ views about benefits and
risks of medical products. CDER focuses on the qualitative preference elicitation methods. Preference researchers
argue that when carefully conducted, stated-preference studies generate valid scientific evidence on patients’ views
about relative desirability of harms, risks, benefits, and other features related to treatment alternatives. However,
Reaney Shuren critics of preference research point out that humans often rely on decision heuristics, have poor numeracy, and fail
tests of internal consistency. The panel will debate the strengths and limitations of stated-preference research and
the extent to which patients’ views can be relied upon to inform regulatory decisions.
Moderator: Shelby D. Reed, PhD, RPh, Duke University, Durham, NC, USA
Speakers: Bennett Levitan, MD, PhD, Janssen Research & Development, Titusville, NJ, USA; Matt Reaney, FRSPH,
MSc, Sanofi , Guildford, Surrey, UK; Jeff Shuren, MD, JD, U.S. Food and Drug Administration (FDA), Silver Spring,
MD, USA
www.ispor.org 9
Your ISPOR Conference App
At your fingertips.
It’s easy to personalize and maximize
your ISPOR conference experience.
Search: ISPOR
WI-FI NETWORK: ISPOR

PASSWORD: IQVIA2018
Released Presentations
Looking for presentations from ISPOR 2018?

www.ispor.org >> ISPOR 2018 >> Released Presentations
Presentations are available online after each session, subject to speaker approval.
More than 85% of presentations are expected to be available!
10 #ISPORBaltimore
ISPOR2018
May 19-23, 2018
Baltimore, MD, USA
Program & Schedule of Events
● Saturday May 19 Pre-Meeting Short Courses are training courses offered across 7 HEOR key
topic areas. The skill level ranges from introductory to advanced, and continuing
education credits are available. Separate registration is required.
Plenary Sessions feature thought-provoking discussions on challenging topics
● Sunday May 20 related to healthcare policy, the application of HEOR in healthcare decision making,
or methodology.
Spotlight Sessions highlight timely topics in HEOR and promote areas of
● Monday May 21 innovation of interest to the ISPOR community.

Issue Panels (IP) introduce debate with multistakeholder perspectives on new or
controversial issues in HEOR.
● Tuesday May 22 Workshops (W) discuss new and innovative applications in the conduct and use
of HEOR or the latest on real-world data, clinical-, economic-, or patient-reported
outcomes, patient-preferences, and healthcare policy.
ISPOR Forums (F) are presented by ISPOR Groups on country/regional health
● Wednesday May 23 policy, scientific research/initiatives, good practices for outcomes research, research
tools, or publications.
Podium Presentations (P) sessions consist of four 15-minute outcomes research
presentations on a single topic.
Poster Presentations sessions contain approximately 350 research posters per
session arranged by disease, topic, or health care intervention with a scheduled
author discussion hour.
Symposia are sponsored presentations related to ISPOR’s mission. The sponsor
organization selects a subject of interest to delegates and arranges suitable
speakers.
Open Meetings Join leaders of ISPOR’s SIGs, interact with other participants
interested in the same topics and provide input on the direction of projects for
ISPOR groups. These groups develop valuable manuscripts, webinars, and tools to
advance the field of HEOR. Open to all attendees.
#ISPORBaltimore 11
Saturday May 19
7:00AM-6:00PM REGISTRATION HELP DESK HOURS Charles Street Lobby, Baltimore Convention Center
7:00AM-5:00PM MULTI-FAITH PRAYER ROOM Ballroom VIP East Suite (Level 400)
7:00AM-5:00PM NURSING MOTHER’S ROOM Ballroom VIP West Suite (Level 400)
8:00AM-5:00PM SHORT COURSE FULL DAY (Separate Registration Required)

Introduction to Pharmacoeconomics Room 314-315 (Level 300)
Track: Economic Methods
Level: Introductory—This course is suitable for those with little or no experience with pharmacoeconomics.
Faculty: Lorne Basskin, PharmD, Brown University, Providence, RI, USA
Bayesian Analysis – Overview and Applications Room 321-322 (Level 300)
Track: Modeling Methods
Level: Introductory—This course is designed for those with a limited understanding of Bayesian statistical concepts or for those who want
a refresher and more practical experience.
Faculty: Christopher S. Hollenbeak, PhD, The Pennsylvania State University, Hershey, PA, USA; David J. Vanness, PhD, University of
Wisconsin-Madison, Madison, WI, USA
8:00AM-12:00PM SHORT COURSE MORNING SESSION (Separate Registration Required)

Introduction to the Design & Database Analysis of Observational Studies of Treatment Effects Using
Retrospective Data Sources Room 316-317 (Level 300)
Track: Observational Data Methods
Level: Introductory
Faculty: Bradley C. Martin, PharmD, PhD, RPh, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Benjamin M.
Craig, PhD, University of South Florida, and Assistant Member, Health Outcomes and Behavior, Moffitt Cancer Center,
Tampa, FL, USA
Introduction to Modeling Methods Room 302-303 (Level 300)
Level: Introductory—This course is suitable for those with little experience with decision analysis, and is recommended as a pre-requisite
to the short courses, “Modeling: Design and Structure of a Model,” “Discrete Event Simulation for Economics Analyses,” “Bayesian
Analysis,” and “Advanced Decision Modeling for Health Economic Evaluations.”
Faculty: Mark S. Roberts, MD, MPP, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA
Introduction to Patient Reported Outcomes Room 320-323 (Level 300)
Track: Patient-Reported Outcomes Methods
Level: Introductory—This course is intended for those with little experience with these methodologies.
Faculty: Alexandra I. Barsdorf, PhD, Pfizer, Inc, New York, NY, USA; Tara Symonds, PhD, Clinical Outcomes Solutions, Folkestone,
Kent, UK
Utility Measures Room 318-319 (Level 300)
Track: Patient Preference Methods
Level: Introductory—No prior knowledge of utilities or health-related quality of life is assumed.
Faculty: John E. Brazier, PhD, MSc, FMedSci, University of Sheffield, Sheffield, UK; Brendan Mulhern, MRes, University of
Technology Sydney, Sydney, Australia
New! Introduction to Constrained Optimization Methods for HealthCare Research Room 307 (Level 300)
Level: Introductory—Some familiarity with the standard techniques of cost-effectiveness analysis is expected, although no specific prior
training is required.
Faculty: William H. Crown, PhD, Optum Labs, Cambridge, MA, USA; Praveen Thokala, MASc, PhD, The University of Sheffield,
Sheffield, UK; Kalyan S. Pasupathy, PhD, Mayo Clinic, Rochester, MN, USA; Deborah A. Marshall, PhD, University of
Calgary, Calgary, AB, Canada
12 #ISPORBaltimore Indicates hands-on exercises requiring the use of your personal computer.
Saturday May 19
Elements of Pharmaceutical/Biotech Pricing I – Introduction Room 309 (Level 300)
Track: Use of Pharmacoeconomic / Economic / Outcomes Research Information
Level: Introductory—This course is designed for those with limited experience in the area of pharmaceutical pricing and covers topics
within a global context.
Faculty: Jack M. Mycka, Medical Marketing Economics LLC (MME), Montclair, NJ, USA; Renato Dellamano, PhD, MME Europe &
ValueVector (Value Added Business Strategies), Milan, Italy
Interoperability and Informatics – Practical Tools and Strategies for Analyzing Real World Data Room 308 (Level 300)
Level: Introductory
Faculty: Scott D. Nelson, PharmD, MS, Vanderbilt University Medical Center, Nashville, TN, USA; Olivier Bodenreider, MD, PhD,
U.S. National Library of Medicine, Bethesda, MD, USA; Richard D. Boyce, PhD, University of Pittsburgh, Pittsburgh, PA, USA
1:00PM-5:00PM SHORT COURSE AFTERNOON SESSION (Separate Registration Required)

Case Studies in Pharmaceutical/Biotech Pricing II - Advanced Room 309 (Level 300)
Level: Intermediate—This course is designed for those with limited experience in the area of pharmaceutical pricing and covers topics
within a global context.
Prerequisite: Participation in the ISPOR Short Course, “Elements of Pharmaceutical / Biotech Pricing I – Introduction,” or equivalent
knowledge, is required.
Faculty: Jack M. Mycka, Medical Marketing Economics LLC (MME), Montclair, NJ, USA; Renato Dellamano, PhD, MME Europe &
ValueVector (Value Added Business Strategies), Milan, Italy
Meta-Analysis and Systematic Reviews in Comparative Effectiveness Research Room 316-317 (Level 300)
Track: Outcomes Research Methods
Level: Introductory—This course is designed for those having little experience with meta-analysis, or as a refresher and update for those
with more experience.
Faculty: Joseph C. Cappelleri, MS, MPH, PhD, Pfizer Inc, Groton, CT, USA; Jeroen P. Jansen, PhD, MSc, Precision Xtract, Oakland,
CA, USA
Collecting Health-State Utility Estimates for Economic Models in Clinical Studies Room 302-303 (Level 300)
Level: Intermediate—This course is for those with some experience with quality of life measures in health economic evaluation.
Faculty: Andrew Briggs, DPhil, University of Glasgow, Glasgow, Scotland, UK; Andrew Lloyd, DPhil, Acaster Lloyd Consulting Ltd,
London, UK; Lynda Doward, MRes, RTI Health Solutions, Manchester, UK
Modeling: Design and Structure of a Model Room 307 (Level 300)
Level: Intermediate—Participants should have a basic understanding of decision analysis.
Prerequisite: Participation in the short course “Introduction to Modeling Methods,” or equivalent knowledge, is required.
Faculty: Shelby L. Corman, PharmD, MS, BCPS, Pharmerit International, Bethesda, MD, USA; Mark S. Roberts, MD, MPP,
University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA
Applications in Using Large Databases Room 320-323 (Level 300)
Level: Intermediate—Participants must have some knowledge of administrative healthcare database analysis.
Prerequisite: Previous attendance at the ISPOR Short Course, “Introduction to Design & Analysis of Observational Studies of Treatment
Effects Using Retrospective Data Sources,” or equivalent knowledge, is recommended.
Faculty: Diana Brixner, PhD, RPh, FAMCP, University of Utah, Salt Lake City, UT, USA; Joanne LaFleur, PharmD, MPH, University of
Utah and George E. Whalen Veterans Health Administration IDEAS Center, Salt Lake City, UT, USA
Use of Propensity Scores in Observational Studies of Treatment Effects Room 310 (Level 300)
Level: Intermediate—This course is designed for those with little experience with this methodology, but some knowledge of observational
databases.
Prerequisite: Previous attendance at the short course “Introduction to the Design & Analysis of Observational Studies of Treatment Effects
Using Retrospective Data Sources,” or equivalent knowledge, is recommended.
Faculty: John D. Seeger, PharmD, DrPH, Optum, Waltham, MA, USA; Jeremy A. Rassen, ScD, Aetion, Inc., New York, NY, USA
Indicates hands-on exercises requiring the use of your personal computer. www.ispor.org 13
Saturday May 19
New! Conjoint Analysis and Stated Preference Methods – Part I Room 318-319 (Level 300)
Level: Introductory
Faculty: A. Brett Hauber, PhD, RTI Health Solutions, Research Triangle Park, NC, USA; John F. P. Bridges, PhD, Johns Hopkins
Bloomberg School of Public Health, Baltimore, MD, USA; Deborah A. Marshall, PhD, University of Calgary, Calgary, AB,
Canada
New! Value of Information: Active Learning, Modeling Tools, and Applications 308 Room 308 300)
(Level (Level 300)
Level: Intermediate
Prerequisite: This course is suitable for those who have completed the ISPOR Introduction to Modeling Methods Short Course or similar
training.
Faculty: Jonathan D. Campbell, PhD, University of Colorado Denver, Aurora, CO, USA; R. Brett McQueen, PhD, University of
Colorado Denver, Aurora, CO, USA
5:30PM-6:30PM EDUCATIONAL SYMPOSIUM Room 309 (Level 300)

Debating the Future of Healthcare
Sponsored by AbbVie
Moderator: Peter Pitts, PhD, Center for Medicine in the Public Interest, New York, NY, USA
Speakers: Nancy Dreyer, PhD, MPH, IQVIA, Cambridge, MA, USA; Marni Hall, PhD, MPH, IQVIA, Rockville, MD, USA; Gregory
Daniel, PhD, MPH, Center for Health Policy, Washington, DC, USA; Marc Berger, MD, New York, NY, USA
< advertisement >
14 #ISPORBaltimore
Sunday May 20
8:00AM-10:00PM EXHIBITOR MOVE IN Halls B-D (Level 100)
8:00AM-12:00PM SHORT COURSE MORNING SESSION (Separate Registration Required)

Using Dice Simulation for Health Economic Analyses Room 307 (Level 300)
Level: Introductory—This course is designed for those with some familiarity with modeling.
Faculty: J. Jaime Caro, MDCM, FRCPC, FACP, Chief Scientist Evidera, Waltham, MA, USA and McGill University, Montreal, QC, Canada;
Jorgen Moller, MSc, Mech Eng, Evidera, Hammersmith, UK
Cost-Effectiveness Analysis Alongside Clinical Trials Room 302-303 (Level 300)
Level: Introductory—Familiarity with economic evaluations will be helpful.
Faculty: Richard J. Willke, PhD, ISPOR, Lawrenceville, NJ, USA; Scott D. Ramsey, MD, PhD, Fred Hutchinson Cancer Research
Center, Seattle, WA, USA
Statistical Methods in Economic Evaluations Room 309 (Level 300)
Level: Intermediate—Participants should have basic knowledge of economic evaluations and statistics.
Faculty: Shelby D. Reed, PhD, RPh, Duke University, Durham, NC, USA; Brad Hammill, DrPh, MS, Duke School of Medicine & Duke
Clinical Research Institute, Durham, NC, USA
Risk Sharing / Performance-Based Arrangements for Drugs and Other Medical Products Room 314-315 (Level 300)
Level: Intermediate
Prerequisite: It will be helpful for individuals to have completed the short course, “Elements of Pharmaceutical / Biotech Pricing I –
Introduction,” or to be familiar with both the key determinants of pharmaceutical pricing and the main international health
systems.
Faculty: Louis P. Garrison, PhD, University of Washington, Seattle, WA, USA; Adrian Towse, MA, MPhil, Office of Health Economics,
London, UK; Josh J. Carlson, MPH, PhD, University of Washington, Seattle, WA, USA
New! Conjoint Analysis and Stated Preference Methods – Part II Room 318-319 (Level 300)
Level: Intermediate
Faculty: A. Brett Hauber, PhD, RTI Health Solutions, Research Triangle Park, NC, USA; John F. P. Bridges, PhD, Johns Hopkins
Bloomberg School of Public Health, Baltimore, MD, USA; Deborah A. Marshall, PhD, University of Calgary, Calgary, AB,
Canada
Patient-Reported Outcomes: Item Response Theory Room 308 (Level 300)
Level: Introductory—This course is designed for those with little to no experience with IRT.
Faculty: Bryce B. Reeve, PhD, Duke University, Durham, NC, USA
Use of Instrumental Variables in Observational Studies of Treatment Effects Room 321-322 (Level 300)
Level: Intermediate—This course is suitable for those with some knowledge of econometrics.
Prerequisite: Previous attendance at the ISPOR Short Course, “Introduction to the Design & Analysis of Observational Studies of
Treatment Effects Using Retrospective Data Sources,” or equivalent knowledge, is recommended.
Faculty: Benjamin M. Craig, PhD, University of South Florida and Moffitt Cancer Center, Tampa, FL, USA; Bradley C. Martin,
PharmD, PhD, RPh, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Antoine C. El Khoury, PhD, MS,
Janssen GCC, Dubai, United Arab Emirates
Indicates hands-on exercises requiring the use of your personal computer.

www.ispor.org 15
Sunday May 20
Budget Impact Analysis I – A 6-Step Approach Room 316-317 (Level 300)
Level: Intermediate—This course is designed for those with some experience with pharmacoeconomic analysis.
Faculty: Josephine Mauskopf, PhD, MHA, RTI Health Solutions, Durham, NC, USA; C. Daniel Mullins, PhD, University of Maryland,
School of Pharmacy, Baltimore, MD, USA; Stephanie R. Earnshaw, PhD, MS, RTI Health Solutions, Research Triangle Park,
NC, USA
New! Economic and Financial Drivers of Value Focus and Development of a Holistic Value Proposition
Room 320-323 (Level 300)
Level: Intermediate
Faculty: Ambarish J. Ambegaonkar, PhD, APPERTURE LLC., Marlboro, NJ, USA
New! Introduction to Health Technology Assessment Room 310 (Level 300)
Level: Introductory—This course is suitable for those with little or no experience with HTA.
Faculty: Uwe Siebert, MD, MPH, MSc, ScD, UMIT, Hall i.T., Austria and Massachusetts General Hospital, Boston, MA, USA
12:00PM-6:00PM SPEAKER READY ROOM HOURS Room 311 (Level 300)
12:00PM-6:00PM DIGITAL HEALTH SHOWCASE (Level 200)
1:00PM-5:00PM SHORT COURSE AFTERNOON SESSION (Separate Registration Required)

Introduction to Big Data Analysis: Graph Analytics Room 302-303 (Level 300)
Level: Intermediate
Faculty: David R. Holmes III, PhD, Mayo Clinic College of Medicine, Rochester, MN, USA
Budget Impact Analysis II – Applications and Design Issues Room 316-317 (Level 300)
Level: Intermediate—This course is designed for those who have basic knowledge of budget impact analyses and desire exposure to these
analyses in Excel.
Prerequisite: Participation in the ISPOR short course, “Budget Impact Analysis I: A 6-Step Approach,” or equivalent knowledge, is
recommended.
Faculty: Stephanie R. Earnshaw, PhD, MS, RTI Health Solutions, Research Triangle Park, NC, USA; Anita J. Brogan, PhD, RTI Health
Solutions, Didsbury, Manchester, UK; Thor-Henrik Brodtkorb, PhD, RTI Health Solutions, Ljungskile, Sweden
US Payers – An Introduction to Their Structures, Evidence Needs, and Decision-Making Process
Room 314-315 (Level 300)
Level: Introductory—This course is designed for those having very minimal experience in understanding differences in perspectives and
evidence needs for various access decision makers in the US healthcare system
Faculty: Priti Jhingran, PhD, Allergan, Plainsboro, NJ, USA; Helen Sherman, PharmD, RPh, Solid Benefit Guidance, Portland, OR, USA
Network Meta-Analysis Room 310 (Level 300)
Track: Outcomes Research Methods
Level: Intermediate—This course requires at least a basic knowledge of meta-analysis and statistics.
Faculty: Jeroen P. Jansen, PhD, Precision Xtract, Oakland, CA, USA; Joseph C. Cappelleri, MS, MPH, PhD, Pfizer Inc, Groton, CT, USA
Advanced Decision Modeling for Health Economic Evaluations Room 320-323 (Level 300)
Level: Advanced—Participants should have an understanding of decision analysis.
Prerequisite: Previous attendance at the short course “Modeling: Design and Structure of a Model,” or equivalent knowledge, is required.
Faculty: Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK; Mark Sculpher, PhD, University of York, York, UK
Advanced Patient-Reported Outcomes Room 321-322 (Level 300)
Level: Advanced
Faculty: Cheryl D. Coon, PhD, Outcometrix, Tucson, AZ, USA; Jason Lundy, PhD, Outcometrix, Tucson, AZ, USA
16 #ISPORBaltimore Indicates hands-on exercises requiring the use of your personal computer.
Sunday May 20
New! Preference Data for Patient-Centric Benefit-Risk Analysis Room 318-319 (Level 300)
Level: Advanced
Prerequisite: Previous attendance at the ISPOR short course, “Conjoint Analysis – Theory and Methods”, or equivalent knowledge of
stated-preference methods, is required.
Faculty: F. Reed Johnson, PhD, Duke University, Durham, NC, USA; Bennett Levitan, MD, PhD, Janssen Research & Development,
Titusville, NJ, USA; Juan Marcos Gonzalez, PhD, Duke University, Durham, NC, USA
Fitting the Structure to the Task: Choosing the Right Dynamic Simulation Model to Inform Decisions About
Healthcare Delivery Room 308 (Level 300)
Level: Intermediate—This course is designed for beginners in simulation modeling, but some experience with HTA and decision modeling.
Faculty: Deborah A. Marshall, PhD, University of Calgary, Calgary, AB, Canada; Jon Tosh, MSc, PhD, DRG Abacus, Manchester, UK;
Koen Degeling, MSc, University of Twente, Enschede, The Netherlands
New! A Health Economics Approach to US Value Assessment Frameworks Room 309 (Level 300)
Level: Introductory
Faculty: Richard J. Willke, PhD, ISPOR, Lawrenceville, NJ, USA; Louis P. Garrison, PhD, School of Pharmacy University of
Washington, Seattle, WA, USA; Charles E. Phelps, PhD, MBA, University of Rochester, Rochester, NY, USA
New! Causal Inference and Causal Diagrams in Big, Real-World Observational Data and Pragmatic Trials
Room 307 (Level 300)
Level: Advanced
Prerequisite: Previous attendance at the ISPOR short course, “Introduction to the Design & Analysis of Observational Studies of Treatment
Effects Using Retrospective Data Sources”, or equivalent knowledge, is recommended.
Faculty: Uwe Siebert, MD, MPH, MSc, ScD, UMIT, Hall i.T., Austria and Massachusetts General Hospital, Boston, MA, USA; Douglas E
Faries, PhD, Eli Lilly and Company, Indianapolis, IN, USA

Healthcare Gridlock Between Value, Affordability, and Access: The Good, the Bad and the Ugly
Sponsored by Amgen
Moderator: Jorge Arellano, Amgen Inc, Thousand Oaks, CA, USA
Speakers: Diana Brixner, PhD, RPh, FAMCP, University of Utah, Salt Lake City, UT, USA; Jeff Dunn, PharmD, MBA, Magellan
RX, Salt Lake City, UT, USA
6:30PM-8:30PM ISPOR STUDENT RESEARCH COMPETITION Ballroom I (Level 400)

The Student Research Competition is a quiz competition featuring teams from ISPOR Student Chapters. Questions are from
the ISPOR Book of Terms and ISPOR Good Research Practices for Outcomes Research. The top three winning teams receive
a cash prize for their ISPOR Student Chapter. Sponsored by The CPRH Exam, ZRx Outcomes Research and ISPOR.

Roles of Biosimilars on Patient Access
Sponsored by Celltrion Healthcare
Moderator: HoUng Kim, MBA, Celltrion Healthcare, Incheon, South Korea
Speakers: Jørgen Jahnsen, PhD, Akershus University Hospital, Lørenskog, Norway; Laszlo Gulacsi, PhD, Corvinus University
of Budapest, Budapest, Czech Republic
8:30PM-9:30PM ISPOR STUDENT & FACULTY ICEBREAKER RECEPTION Ballroom Foyer (Level 400)
All students and faculty are welcome to attend the reception where ISPOR will be distributing prizes and students and
faculty can network with their peers in a relaxed environment. The winning design for the t-Shirt competition will be handed
out to all students in attendance. Sponsored by RTI Health Solutions
www.ispor.org 17
< advertisement >
18 #ISPORBaltimore
Monday May 21
8:00AM-6:00PM SPEAKER READY ROOM HOURS Room 311 (Level 300)
8:30AM-7:45PM EXHIBIT/POSTER HALL HOURS Halls B-D (Level 100)
8:30AM-2:00PM RESEARCH POSTER PRESENTATIONS - SESSION I Halls B-D (Level 100)
8:30AM-10:30AM WELCOME & FIRST PLENARY SESSION Hall A (Level 100)

Welcome from ISPOR CEO/Executive Director
Nancy S. Berg, ISPOR, Lawrenceville, NJ, USA
Presidential Address
Shelby D. Reed, PhD, RPh, Duke University, Durham, NC, USA
Conference Program Overview from Program Committee Co-Chairs
C. Daniel Mullins, PhD, University of Maryland School of Pharmacy, Baltimore, MD, USA; Rachael L. Fleurence, PhD,
National Evaluation System for Health Technology Coordinating Center (NESTcc), Medical Device Innovation Consortium
(MDIC), Arlington, VA, USA
2018 ISPOR Avedis Donabedian Outcomes Research Lifetime Achievement Award
AWARDEE: F. Reed Johnson, PhD, Duke School of Medicine, Duke Clinical Research Institute, Duke University, Durham,
NC, USA
First Plenary Session: Inflection Point for Real-World Evidence? The Transformational Role of Digital Health
Moderator: Rachael L. Fleurence, PhD, National Evaluation System for Health Technology Coordinating Center (NESTcc),
Medical Device Innovation Consortium (MDIC), Arlington, VA, USA
Speakers: Adrian F. Hernandez, MD, MHS, Duke University School of Medicine, Durham, NC, USA; Michelle McMurry-
Heath, MD, PhD, Johnson & Johnson Medical Device Companies, Washington, DC, USA; Danica Marinac-Dabic, MD, PhD,
MMSc, FISPE, U.S. Food & Drug Administration, Silver Spring, MD, USA; Sally Okun, RN, MMHS, PatientsLikeMe, Cambridge,
MA, USA
10:30AM-11:00AM BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I Halls B-D (Level 100)
Sponsored by Pharmerit International
10:30AM-6:00PM DIGITAL HEALTH SHOWCASE (Level 200)

IP1: Designing a Patient-Centered Value Framework to Guide Shared Decision Making in Oncology: Why, What,
and How? Hall A (Level 100)
Moderator: Jalpa A. Doshi, PhD, University of Pennsylvania, Philadelphia, PA, USA
Panelists: Henry A. Glick, PhD, University of Pennsylvania, Philadelphia, PA, USA; Ellen Sonet, JD, MBA, CancerCare, New
York, NY, USA; Charles E. Phelps, PhD, MBA, University of Rochester, Rochester, NY, USA
IP2: What Role for Value Assessment in US Private Payers’ Specialty Drug Coverage Decisions? Ballroom I (Level 400)
Moderator: James D. Chambers, PhD, MPharm, MSc, Tufts Medical Center, Boston, MA, USA
Panelists: Susan A. Cantrell, CAE, Academy of Managed Care Pharmacy, Alexandra, VA, USA; Sara Traigle van
Geertruyden, JD, Partnership to Improve Patient Care, Washington, DC, USA; Randy Burkholder, BA, PhRMA, Washington,
DC, USA
www.ispor.org 19
Monday May 21
W1: Time to Look beyond Kaplan-Meier Curves? Challenges and Opportunities in Overall Survival Extrapolations
for Immuno-Oncology Trials – Scientific Rationale for Using Patient-Level Biomedical Information
Ballroom II (Level 400)
Discussion Leaders: Andrew Briggs, DPhil, Health Economics & Health Technology Assessment, Institute of Health and
Wellbeing, University of Glasgow, Glasgow, Scotland, UK; Scott D. Ramsey, MD, PhD, Fred Hutchinson Cancer Research
Center and University of Washington, Seattle, WA, USA; Yiduo Zhang, PhD, AstraZeneca, Gaithersburg, MD, USA; Pralay
Mukhopadhyay, PhD, AstraZeneca, Gaithersburg, MD, USA
W2: What Is Patient Experience Data? The Regulatory Perspective Ballroom III (Level 400)
Discussion Leaders: Martin Ho, MS, U.S. Food and Drug Administration, Silver Spring, MD, USA; Megan Moncur, MS, U.S.
Food and Drug Administration, Silver Spring, MD, USA; Pujita Vaidya, MPH, U.S. Food and Drug Administration, Silver
Spring, MD, USA
W3: Digital Health: Evaluating the Evidence, Identifying Gaps, Producing Better Science Room 309 (Level 300)
Discussion Leaders: Penny Mohr, MA, Patient Centered Outcomes Research Institute, Washington, DC, USA; Karen
Schoelles, MD, SM, FACP, ECRI Institute, Plymouth Meeting, PA, USA; Murray Aitken, MBA, IQVIA Institute for Human Data
Science, New York, NY, USA; Jasmine Bihm, DrPH, MPH, Agency for Healthcare Research and Quality, Rockville, MD, USA
P1: Cost-Effectiveness Studies Ballroom IV (Level 400)

Moderator: Kenneth M. Shermock, PharmD, PhD, The Johns Hopkins Hospital, Baltimore, MD, USA
11:00AM-11:15AM CE1 Cost-Effectiveness of Three Different Strategies for the Treatment of First Recurrent Clostridium Difficile
Infection Diagnosed in a Community Setting
Lam SW1, Delgado D2, Chalfin DB2,1Cleveland Clinic, Cleveland, OH, USA, 2Jefferson College of Population Health at Thomas
Jefferson University, Philadelphia, PA, USA
11:15AM-11:30AM CE2 Mandatory Meningococcal Serogroup B Vaccination for College Students is Not Cost-Effective
Leeds IL1, Thayer WM2, Sankhla P3, Bamogo A3, Namasivayam V3, 1Johns Hopkins University School of Medicine, Baltimore,
MD, USA, 2Johns Hopkins School of Nursing, Baltimore, MD, USA, 3Johns Hopkins University Bloomberg School of Public
Health, Baltimore, MD, USA
11:30AM-11:45AM CE3 Cost-Effectiveness Analysis of Regorafenib and Tas-102 in Refractory Metastatic Colorectal Cancer
Cho SK, Hay JW, Barzi A, University of Southern California, Los Angeles, CA, USA
11:45AM-12:00PM CE4 An Economic Evaluation of a Familial Cancer Risk Management Program for BRCA Mutation Carriers: An
Australian Perspective
Petelin L1, Liew D2, Mitchell G3, James PA3, Trainer AH3, 1University of Melbourne, Parkville, Australia, 2Monash University,
Melbourne, Australia, 3Peter MacCallum Cancer Centre, Parkville, Australia
P2: Addiction and Mental Health Studies Room 310 (Level 300)
Moderator: Eric Slade, PhD, University of Maryland, Baltimore, MD, USA
11:00AM-11:15AM MH1 Descriptive Results from the Prescription Opioid Misuse and Abuse Questionnaire (POMAQ) Validation Study
Coyne KS1, Barsdorf AI2, Poon J3, Maziere JA4, Pierson RF5, Schnoll S6, Butler SF7, Farrar JT8, Porter LN9, Franks Jr MJ10, 1Evidera,
Bethesda, MD, USA, 2Pfizer, Inc, New York, NY, USA, 3Eli Lilly and Company, Indianapolis, IN, USA, 4PPD, Wilmington, NC,
USA, 5Janssen Global Services, LLC, Raritan, NJ, USA, 6Pinney Associates, Bethesda, MD, USA, 7Inflexxion, Inc., Waltham,
MA, USA, 8University of Pennsylvania, Philadelphia, PA, USA, 9Health ResearchTx, Trevose, PA, USA, 10Naval Medical Center,
Portsmouth, VA, USA
11:15AM-11:30AM MH2 Economic Burden of Opioid Use Among Pregnant Women: Evidence from the Medical Expenditure Panel
Survey, 2011-2015
Chen G, Xiao H, University of Florida, Gainesville, FL, USA
11:30AM-11:45AM MH3 Geographic Variation of High-Risk Opioid Use and Risk of Overdose Among Disabled Medicare Beneficiaries in
the US from 2011 to 2015
Lo-Ciganic W1, Gellad WF2, Zhou L3, Donohue JM4, Roubal A5, Hines L6, Lindermann J7, Malone DC3, Bhattacharjee S3, Lee
JK3, Kwoh CK3, 1The University of Arizona, Tucson, AZ, USA, 2Center for Health Equity Research and Promotion, VA Pittsburgh
Healthcare System, Pittsburgh, PA, USA, 3University of Arizona, Tucson, AZ, USA, 4University of Pittsburgh, Pittsburgh, PA,
USA, 5Robert Wood Johnson Foundation, Princeton, NJ, USA, 6Pharmacy Quality Alliance, Springfield, VA, USA, 7ESRI Inc.,
Broomfield, CO, USA
11:45AM-12:00PM MH4 Examining Parkinson’s Disease Psychosis Treatment Outcomes in the Real World: The Insyte Observational
Study
Goldman J1, Fredericks D2, Trotter J3, Heywood C3, Ryan A3, Block S3, Rattana S3, Shim A2, Larsen N2, 1Rush University Medical
Center, Chicago, IL, USA, 2ACADIA Pharmaceuticals Inc., San Diego, CA, USA, 3Continuum Clinical, Northbrook, IL, USA
20 #ISPORBaltimore
Monday May 21
11:00AM-12:00PM ISPOR NEW PROFESSIONAL EVENT Room 316-317 (Level 300)

Career Advice Across the Globe: Effectively Communicating & Presenting Your Research
Speakers: Michael Drummond, PhD, University of York, York, Heslington, UK; Surachat Ngorsuraches, PhD, South Dakota
State University, Brookings, SD, USA
12:00PM-2:15PM LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I Halls B-D (Level 100)

21st Century Cures Act and the Future of Real-World Evidence
Sponsored by Syneos Health
Moderator: David Thompson, PhD, Syneos Health, Boston, MA, USA
Speakers: Jennifer S. Graff, PharmD, National Pharmaceutical Council, Washington, DC, USA; Cathy W Critchlow,
PhD, Amgen Inc, Thousand Oaks, CA, USA; David Martin, MPH, U.S. Public Health Service and U.S. Food and Drug
Administration, Silver Spring, MD, USA
12:30PM-1:30PM ISPOR STUDENT RESEARCH SHOWCASE Room 310 (Level 300)

Moderators: Annesha White,MS,
Zeba M. Khan, MS,RPh,
PharmD, PhD, University
PhD, Celgene of North
Corporation, Texas NJ,
Summit, System
USA;College of Pharmacy,
Laura Pizzi, Fort PharmD,
MPH, RPh, Worth, TX,Rutgers
USA;
Laura Pizzi,
University, MPH,
New RPh, PharmD,
Brunswick, NJ, USARutgers University, New Brunswick, NJ, USA
Speakers: Judith John, PharmD, KMCT Medical college, Manassery, Kerala, India; Youngran Kim, MPH, University of Texas
Health Science Center at Houston, Houston, TX, USA; Wan-Ting Hsu, MS, Harvard University, Boston, MA, USA
12:30PM-2:00PM ISPOR WOMEN IN HEALTH ECONOMICS AND OUTCOMES RESEARCH Room 309 (Level 300)
ISPOR’s Women in HEOR initiative is designed to support the growth, development, and contribution of women in HEOR; to
serve as a catalyst for women’s leadership in the field, and to offer a platform for ISPOR women to collaborate, network,
share, and mentor each other. Shelby D. Reed, PhD will moderate this session with Laurie Cooke, CEO of the Healthcare
Businesswomen’s Association (HBA), as the special guest speaker. Ms Cooke will lead a panel discussion that includes Shelby
D. Reed, PhD, Rachael L. Fleurence, PhD, National Evaluation System for Health Technology Coordinating Center (NESTcc);
Zeba M. Khan, PhD, Celgene Corporation; and Joe DePinto, Cardinal Health.
1:00PM-2:00PM POSTER AUTHOR DISCUSSION HOUR - SESSION I Halls B-D (Level 100)
2:15PM-3:15PM SPOTLIGHT SESSION Hall A (Level 100)

Reinventing the Future of Knowledge Generation in Healthcare
Disruptive innovation and smarter use of patient data have the potential to transform healthcare delivery from reactive to
proactive and personalized care. Dr. Harlan Krumholz, Yale School of Medicine and Yale-New Haven Hospital, will identify
key impediments to progress in generating the knowledge we need in healthcare and describe the vital role of patients and
the public as partners. Dr. Krumholz will also identify emerging opportunities to transform the performance of knowledge
generation in healthcare.
Moderator: Rachael L. Fleurence, PhD, National Evaluation System for Health Technology Coordinating Center, Medical
Device Innovation Consortium, Arlington, VA, USA
Speaker: Harlan M. Krumholz, MD, SM, Harold H. Hines, Jr. Professor of Medicine and Epidemiology and Public Health, Yale
School of Medicine and Director, Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT, USA
3:15PM-3:45PM BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION II Halls B-D (Level 100)
3:30PM-7:30PM RESEARCH POSTER PRESENTATIONS - SESSION II Halls B-D (Level 100)

IP3: The Machine Learning Debate: Panacea or the New Alchemy? Ballroom II (Level 400)
Moderator: Sreeram Ramagopalan, PhD, Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK
Panelists: Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK; Gorana Capkun-Niggli, PhD, Novartis Pharma AG,
Basel, Switzerland; Radek Wasiak, PhD, Evidera, London, UK
IP4: Incorporating Quantitative Patient Preference Information into Healthcare Decision-Making Processes: Is
Health Technology Assessment Falling Behind? Hall A (Level 100)
Moderator: Paula Lorgelly, BSc(Hons), PhD, PGCAP, Office of Health Economics, London, UK
Panelists: David J. Mott, MSc, Office of Health Economics, London, UK; A. Brett Hauber, PhD, RTI Health Solutions,
Research Triangle Park, NC, USA; Deborah A. Marshall, PhD, University of Calgary, Calgary, AB, Canada
www.ispor.org 21
Monday May 21
W4: Biosimilars, Utilization, and Post-Marketing Surveillance in the United States (Invited Workshop)
Ballroom I (Level 400)
Discussion Leaders: Cate Lockhart, PharmD, PhD, Biologics and Biosimilars Collective Intelligence Consortium, Alexandria,
VA, USA; Mark J. Cziraky, PharmD, CLS, Healthcore, Wilmington, DE, USA; Mike Blum, MD, MPH, U.S. Food & Drug
Administration, Silver Spring, MD, USA
W5: Adjusting for Between-Trial Differences in the Schedule of Assessment for Disease Progression in Immuno-
Oncology and Its Impact on Indirect Treatment Comparisons Ballroom III (Level 400)
Discussion Leaders: Venediktos Kapetanakis, PhD, Evidera, London, UK; Michael Schlichting, Merck KGaA, Darmstadt,
Germany; John William Stevens, PhD, University of Sheffield, Sheffield, UK
W6: Economic Evaluation of Vaccination Programs: Exploring Multiple Methods Ballroom IV (Level 400)
Discussion Leaders: Josephine Mauskopf, PhD, MHA, RTI Health Solutions, Durham, NC, USA; David E Bloom, PhD, Harvard
University, Boston, MA, USA; Americo Cicchetti, PhD, Università Cattolica del Sacro Cuore, Rome, Italy
P3: Medical Device and Diagnostics Studies Room 309 (Level 300)
Moderator: Jan Pietzsch, PhD, Wing Tech Inc., Irvine, CA, USA
3:45PM-4:00PM MD1 A Real-World Assessment of the Clinical and Economic Impact of Powered vs Manual Endoscopic Staplers
When Used in Conjunction with Buttress in Bariatric Surgery
Lim S1, Roy S1, Yadalam S2, Johnston SS2, 1Ethicon Inc, Somerville, NJ, USA, 2Johnson & Johnson Co., New Brunswick, NJ, USA
4:00PM-4:15PM MD2 A Comparison of Long-Term Patient Outcomes After Heart Valve Replacement with Biological or Mechanical
Valves in Medicare Beneficiaries
Du D1, Lu X1, McKean S2, Warnock R2, Laschinger J1, Loyo-Berríos N1, Marinac-Dabic D1, 1U.S. Food and Drug Administration,
Silver Spring, MD, USA, 2Acumen LLC, Burlingame, CA, USA
4:15PM-4:30PM MD3 Linkage between Orthopedic Registry and Administrative Data Using Indirect Identifiers for National Device
Infrastructure Development
Mao J1, Etkin C2, Lewallen DG3, Sedrakyan A4, 1Weill Cornell Medical College, New York, NY, USA, 2American Joint Replacement
Registry, Rosemont, IL, USA, 3Mayo Clinic, Rochester, MN, USA, 4Weill Cornell Medicine, New York, NY, USA
4:30PM-4:45PM MD4 Payer Coverage and Evidence Requirements for Oncology Liquid Biopsy Testing in the United States: Current
State and Filling the Gaps
Spinner DS1, Faulkner EC2, Ringo MC2, Mihos MC1, Joines J3, 1Evidera, Chapel Hill, NC, USA, 2Evidera, Raleigh, NC, USA, 3PPD,
Raleigh, NC, USA
P4: Benefits, Value, and Coverage Studies Room 310 (Level 300)
Moderator: Ya-Chen Tina Shih, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
3:45PM-4:00PM VA1 Does the Timing of a Drug’s Costs and Benefits Influence US Payer Coverage of Special Drugs?
Kim DD, Chambers J, Pope E, Cohen JT, Neumann PJ, Tufts Medical Center, Boston, MA, USA
4:00PM-4:15PM VA2 Trends in the Economic Value of Newly Approved Cancer Therapies in the United States
Chen AJ1, Hu X1, Jena AB2, Goldman DP1, 1University of Southern California, Los Angeles, CA, USA, 2Harvard Medical School,
Boston, MA, USA
4:15PM-4:30PM VA3 “It’s Tough to Make Predictions, Especially About the Future”: Comparing Life Expectancy Predictions Based on
Period versus Cohort Life Tables
Garrison LP, Li M, University of Washington, Seattle, WA, USA
4:30PM-4:45PM VA4 Economic Consequences of Anti-HCV Antiviral Treatment Investment from the NHS Perspective
Mennini FS1, Marcellusi A1, Viti R1, Kondili L2, Rosato S2, Vella S2, on behalf of PITER collaboration study group2, 1Faculty of
Economics, Centre for Economic and International Studies (CEIS)-Economic Evaluation and HTA (EEHTA), University of Rome
Tor Vergata, Rome, Italy, 2Center for Global Health, Istituto Superiore di Sanità, Rome, Italy

IP5: Should We Move Beyond Conventional Cost-Effectiveness Analysis? If So, How? Ballroom II (Level 400)
Moderator: Darius N. Lakdawalla, PhD, University of Southern California, Los Angeles, CA, USA
Panelists: Peter J. Neumann, ScD, Tufts Medical Center, Boston, MA, USA; Charles E. Phelps, PhD, MBA, University of
Rochester, Rochester, NY, USA; Jeroen P Jansen, PhD, Precision Health Economics, Los Angeles, CA, USA
IP6: Increasing Medical Device Evidence for Payers, Providers, and HTA Bodies: Who’s Responsible for
Generating the Evidence? Ballroom I (Level 400)
Moderator: Karen Worley, PhD, Humana, Cincinnati, OH, USA
Panelists: Bruce Gingles, BA, Cook Medical, Bloomington, IN, USA; Suzanne Belinson, PhD, Blue Cross and Blue Shield
Association, Chicago, IL, USA; Harindra C Wijeysundera, MD, PhD, FRCPC, FCCS, FAHA, CADTH, Ottawa, ON, Canada
22 #ISPORBaltimore
Monday May 21
IP7: The Changing Landscape of Healthcare Decision Making: How Can We Leverage the Use of Real-World
Evidence for Regulatory, Coverage, and Clinical Decision Making? Hall A (Level 100)
Moderator: Rachael Fleurence, PhD, Medical Device Innovation Consortium (MDIC), Arlington, VA, USA
Panelists: Owen Faris, PhD, U.S. Food and Drug Administration, Silver Spring, MD, USA; Kathleen Blake, MD, MPH,
American Medical Association (AMA), Washington, DC, USA; Naomi Aronson, PhD, Blue Cross and Blue Shield Association,
Chicago, IL, USA
W7: Artificial Intelligence and Precision Medicine: Does the Health Economist Need to Adapt to the Machine?
Ballroom III (Level 400)
Discussion Leaders: Augustin Terlinden, MSc, Independent Researcher, Brussels, Belgium; Patricia A Deverka, MD, MS,
MBE, American Institutes for Research, Chapel Hill, NC, USA; Amine Aissaoui, PharmD, MSc, Paris Dauphine University,
PSL, Paris, France; Olivier Ethgen, MSc, PhD, SERFAN innovation, Namur, Belgium
W8: Assessing Patient Functioning in Drug Development Using Performance Outcome Assessments: Evidentiary,
Methodological, and Operational Considerations Ballroom IV (Level 400)
Discussion Leaders: Elektra Papadopoulos, MD, MPH, U.S. Food and Drug Administration, Silver Spring, MD, USA; Heather
Adams, PhD, University of Rochester Medical Center, Rochester, NY, USA; Daniel S. Rooks, PhD, Novartis Institutes for
BioMedical Research, Cambridge, MA, USA; Daniel C. Chung, DO, MA, Spark Therapeutics, Philadelphia, PA, USA
P5: Cost Studies Room 309 (Level 300)

Moderator: C. Edward Chou, PhD, Auburn University, Auburn, AL, USA
CS1 WITHDRAWN
5:00PM-5:15PM CS2 Clinical, Humanistic, and Economic Burden of Osteoarthritis (OA) Among Noninstitutionalized Adults in the
United States
Zhao X1, Shah D1, Gandhi K2, Wei W3, Dwibedi N1, Webster L4, Sambamoorthi U5, 1West Virginia University, School of
Pharmacy, Morgantown, WV, USA, 2Teva Pharmaceutical Industries, Frazer, PA, USA, 3Regeneron Pharmaceuticals, Tarrytown,
NY, USA, 4PRA Health Sciences, Salt Lake City, UT, USA, 5West Virginia University, Morgantown, WV, USA
5:15PM-5:30PM CS3 Projected Medicare Savings Associated with Lowering the Risk of Total Hip Arthroplasty Revision: An
Administrative Claims Database Analysis
Ackerman SJ1, Knight T2, Wahl PM2, 1Covance Market Access Services Inc., San Diego, CA, USA, 2Covance Market Access
Services Inc., Gaithersburg, MD, USA
5:30PM-5:45PM CS4 Alzheimer’s Attributable Costs in the United States: A Secondary Analysis of Medical Expenditure Panel Survey
2011-2015
Shuvo TA, Haider MR, Khan MM, University of South Carolina, Columbia, SC, USA
P6: Analytic and Modeling Methods Room 310 (Level 300)

Moderator: Michael Eaddy, PharmD, PhD, Xcenda, Palm Harbor, FL, USA
5:00PM-5:15PM MO1 US Valuation of EQ-5D-5L Health States: An Initial Model Using a Standardized Protocol
Pickard AS1, Law EH1, Jiang R1, Oppe M2, Shaw JW3, Xie F4, Boye KS5, Gong CL6, Chapman RH7, Balch A8, 1University of Illinois at
Chicago, Chicago, IL, USA, 2EuroQol Research Foundation, Rotterdam, The Netherlands, 3Bristol-Myers Squibb, Lawrenceville,
NJ, USA, 4McMaster University, Hamilton, ON, Canada, 5Eli Lilly and Company, Indianapolis, IN, USA, 6University of Southern
California, Los Angeles, CA, USA, 7Institute for Clinical and Economic Review, Boston, MA, USA, 8Patient Advocate Foundation,
Hampton, VA, USA
5:15PM-5:30PM MO2 A Prediction Model for Length of Stay in the ICU Among Septic Patients: A Machine Learning Approach
Ling Y1, Chen Y2, Chirikov V1, Xie J3, Qiu H3, Otgonsuren Z1, Dong P2, Gao X1, 1Pharmerit International, Bethesda, MD, USA,
2
Pfizer Investment Co., Ltd., Beijing, China, 3Zhongda Hospital, Nanjing, China
5:30PM-5:45PM MO3 Identifying and Assessing the Feasibility of Proposed Alternative Approaches to QALY Estimation Within
Cost-Effectiveness Models Using a Systematic Literature Review
Brouwer E, Carlson JJ, University of Washington, Seattle, WA, USA
5:45PM-6:00PM MO4 Globalization Module for a Diabetes Progression Prediction Model: The Building, Relating, Acting, and
Validating Outcomes (BRAVO) Model
Shao H1, Yang S2, Fonseca V3, Shi L1, 1Tulane University School of Public Health and Tropical Medicine, New Orleans, LA,
USA, 2Louisiana State University Health Science Center, New Orleans, LA, USA, 3Tulane University School of Medicine, New
Orleans, LA, USA
www.ispor.org 23
Monday May 21
6:00PM-7:45PM EXHIBITORS’ OPEN HOUSE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION II
Halls B-D (Level 100)
Sponsored by CHEORS
6:00PM-7:00PM MEET THE WOMEN IN HEOR SPEAKERS RECEPTION Halls B-D (Level 100)
Join us for the ISPOR Women in Health Economics and Outcomes Research (HEOR) reception at the ISPOR booth (#213) in
the exhibit hall. Meet the speakers from the Women in HEOR open meeting held earlier in the day and network with others
who support the advancement of women in healthcare.

F1: Health State Utility (HSU) Good Practices Task Force Recommendations for Identification and Use of HSU
Data in Cost-Effectiveness in Decision Modeling Ballroom I (Level 400)
Presented by the ISPOR HSU Estimates in Cost Effectiveness Models Good Practices Task Force
Moderator: John E. Brazier, PhD, MSc, University of Sheffield, Sheffield, UK
Speakers: Andrew Lloyd, DPhil, Acaster Lloyd Consulting Ltd., London, UK; Bruce Crawford, MPH, MA, Syneos Health,
Tokyo, Japan; A. Simon Pickard, PhD, University of Illinois at Chicago, Chicago, IL, USA
F2: Handling Missing Values in Real-World Data: Are There Challenges for Regulatory Decisions for Medical
Products? Ballroom II (Level 400)
Presented by the ISPOR Statistical Methods in Health Economics and Outcomes Research Special Interest Group
Moderator: Laurence Djatche, PharmD, Thomas Jefferson University, Philadelphia, PA, USA
Speakers: Nneka C. Onwudiwe, PhD, PharmD, MBA, Government, Silver Spring, MD, USA; Helene Karcher, PhD, Analytica
Laser, Basel, Switzerland; Judith J. Stephenson, SB, SM, HealthCore, Inc., Wilmington, DE, USA; Samuel Wilson, PhD, BS,
MS, Astellas Pharmaceuticals US, Inc., Northbrook, IL, USA
F3: Defining Patient Centeredness and Engagement in HEOR: Proposed Definition and Stakeholder Response
Ballroom III (Level 400)
Presented by the ISPOR Patient Centered Special Interest Group
Moderator: Rachel L. Harrington, BA, University of Illinois at Chicago, Chicago, IL, USA
Speakers: Eleanor M. Perfetto, PhD, RPh, MS, National Health Council and University of Maryland School of Pharmacy,
Baltimore, MD, USA; Suzanne Schrandt, JD, Arthritis Foundation, Atlanta, GA, USA; Sarah Donelson, MA, Genentech, San
Francisco, CA, USA
F4: The ISPOR HEOR Competencies Framework™: Guiding Professional Development for the Field of HEOR
Room 309 (Level 300)
Presented by the ISPOR HEOR Competency Assessment Working Group
Moderator: Bill Marder, PhD, MA, BA, IBM Watson Health, Cambridge, MA, USA
Speakers: James F. Murray, PhD, Eli Lilly and Company, Carmel, IN, USA; Laura T. Pizzi, PharmD, MPH, Rutgers University,
Piscataway, NJ, USA
F5: Advancing Patient Access to Innovative Health Technologies in Asia – The Role of Real-World Data in the
Value Framework Room 310 (Level 300)
Presented by the ISPOR Asia Consortium Industry Committee
Moderator: Boxiong Tang, MD, PhD, Teva Pharmaceutical, Frazer, PA, USA
Speakers: Jianwei Xuan, PhD, Sun Yat-sen University, Guangzhou, China; Larry Liu, PhD, MD, Merck, Rahway, NJ, USA;
Makoto Kobayashi, PhD, CRECON Medical Assessment Inc., Tokyo, Japan; Sang-Soo Lee, PhD MBA, Medtronic Korea,
Seoul, Republic of South Korea
6:30PM-7:30PM POSTER AUTHOR DISCUSSION HOUR - SESSION II Halls B-D (Level 100)
7:30PM-9:00PM ISPOR GLOBAL NETWORKS RECEPTION Sharps Terrace/Outdoor Terrace (Level 300)
ISPOR invites you to a unique networking opportunity – an ISPOR Global Networks Reception! Meet with members of ISPOR
Consortia in Asia, Latin America, and Central and Eastern Europe, as well as ISPOR Networks in the Middle East and Africa,
to exchange knowledge, share experiences, and learn about ISPOR global groups during this joint event. This reception is
open to all meeting attendees interested in our Global Networks. Join us for this truly multicultural experience and connect
with regional experts in health economics, learn how members of the ISPOR Global Networks benefit from and contribute to
ISPOR, and find out how you can get involved!
24 #ISPORBaltimore
Tuesday May 22
7:15AM-8:15AM EDUCATIONAL SYMPOSIUM Room 309 (Level 300)

Seeing the Forest for the Trees: Developing Robust RWE Using Data Linkage
Sponsored by Covance Market Access
Speakers: Peter M. Wahl, MLA, MS, ScD, Covance Market Access Services Inc., Gaithersburg, MD, USA; Andrew Kress, BA,
HealthVerity, Philadelphia, PA, USA
7:30AM-8:30AM ISPOR PERSONALIZED/PRECISION MEDICINE SPECIAL INTEREST GROUP Room 308 (Level 300)
ISPOR members with a particular interest in health economics and outcomes research as it pertains to cell therapies,
gene therapies, and tissue-engineered products are invited to discuss these topics and future projects with leaders of the
Personalized/Precision Medicine SIG.
8:30AM-2:00PM RESEARCH POSTER PRESENTATIONS - SESSION III Halls B-D (Level 100)
8:30AM-10:30AM WELCOME & SECOND PLENARY SESSION Hall A (Level 100)

Welcome from ISPOR President
Welcome from ISPOR Chief Science Officer
Richard J. Willke, PhD, ISPOR, Lawrenceville, NJ, USA
Incoming Presidential Address
Federico Augustovski, MD, MSc, PhD, Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Buenos Aires,
Argentina
2018 ISPOR Bernie J. O’Brien New Investigator Award
AWARDEE: Sherri Rose, PhD, Harvard Medical School, Boston, MA, USA
2018 ISPOR Award for Excellence in Methodology in Pharmacoeconomics and Health Outcomes Research
AWARDEE: Laura Hatfield, PhD, Harvard Medical School, Boston, MA, USA
2018 ISPOR Award for Excellence in Application of Pharmacoeconomics and Health Outcomes Research
AWARDEE: Rebecca Myerson, MPH, PhD, University of Southern California, Los Angeles, Los Angeles, CA, USA
2018 ISPOR Award for Value in Health Paper of the Year
AWARDEE: Richard Cookson, PhD, University of York, York, UK
(Co-author Dr. Andrew Mirelman, MPH, PhD, from the University of York will accept the award on behalf of Dr. Cookson.)
2018 ISPOR Marilyn Dix Smith Leadership Award
AWARDEE: Finn Børlum Kristensen, PhD, MD, University of Southern Denmark, Odense, Denmark
Second Plenary Session: Digital Health – Help or Hype?
Moderator: C. Daniel Mullins, PhD, University of Maryland School of Pharmacy, Baltimore, MD, USA
Speakers: Chris A. Jones, DPhil, MSc, FRSM, Arizona State University, Tempe, AZ, USA, trUStr.US, University of Vermont
Health Network, Burlington, VT, USA; Ejim E. Mark, MD, MPH, MBA, Access Healthcare Foundation, Rockville, MD, USA;
Nadia A. Sam-Agudu, MD, University of Maryland School of Medicine, and Institute of Human Virology Nigeria, Abuja,
Nigeria
10:30AM-11:00AM BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION III Halls B-D (Level 100)
www.ispor.org 25
Tuesday May 22

IP8: How Important Are Core Outcome Sets to Measuring Value of Innovative New Drugs? Ballroom IV (Level 400)
Moderator: Elise Berliner, PhD, Agency for Healthcare Research and Quality, Rockville, MD, USA
Panelists: Chuck Shih, PhD, MHS, Biogen, Washington, DC, USA; Elizabeth Seeley, MS, PhD, Harvard University, Boston, MA,
USA; Sean R Tunis, MD, MSc, Center for Medical Technology Policy, Baltimore, MD, USA
IP9: Lies, Damned Lies and Cost-Effectiveness: Open-Source Models Are Essential If Cost-Effectiveness Analyses
Are to Be Widely Accepted Ballroom III (Level 400)
Moderator: Neil Hawkins, PhD, University of Glasgow, Glasgow, UK
Panelists: Renée J G Arnold, PharmD, Navigant Consulting, Inc., San Francisco, CA, USA; J. Jaime Caro, MDCM, McGill
University, Montreal, QC, Canada
W9: Numbers or Noise? Interpreting Internal Validity Tests of Stated-Preference Data Ballroom I (Level 400)
Discussion Leaders: Kathryn O’Callaghan, PhD, U.S. Food and Drug Administration, Silver Spring, MD, USA; F. Reed Johnson,
PhD, School of Medicine, Duke University, Durham, NC, USA; Kevin Marsh, PhD, Evidera Ltd, London, UK; Jui-Chen Yang,
MEM, Duke Clinical Research Institute, Durham, NC, USA
W10: Million Dollar Therapies for Rare Conditions: Rethinking Value Ballroom II (Level 400)
Discussion Leaders: Louis P. Garrison, PhD, University of Washington, Seattle, WA, USA; Clifford Goodman, PhD, The Lewin
Group, Falls Church, VA, USA; Paul Melmeyer, MPP, National Organization for Rare Disorders, Washington, DC, USA
W11: Choosing the Appropriate Modeling Method: Causal Modeling, Health Economic Modeling, Constrained
Optimization or Simulation? Hall A (Level 100)
Discussion Leaders: William H Crown, PhD, OptumLabs, Cambridge, MA, USA; Praveen Thokala, MASc, PhD, The University
of Sheffield, Sheffield, UK; Deborah A Marshall, PhD, University of Calgary, Calgary, AB, Canada; Kalyan S. Pasupathy, PhD,
Mayo Clinic, Rochester, MN, USA
P7: Cancer Studies Room 309 (Level 300)

Moderator: Brian Seal, PhD, RPh, MBA, Astra Zeneca, Gaithersburg, MD, USA
11:00AM-11:15AM CN1 Economic Guidance Panel Changes to Minimize Post-Progression Treatment Effects by the Pan-Canadian
Oncology Drug Review in Economic Evaluations Assessing Cancer Drugs
Samjoo I, Whitney S, Grima A, Grima D, Cornerstone Research Group, Burlington, ON, Canada
11:15AM-11:30AM CN2 Estimating the Impact of Affordable Care Act (ACA) on Likelihood of Receiving Mammography and Pap Smear
Screenings
Alharbi A, Khan MM, University of South Carolina, Columbia, SC, USA
11:30AM-11:45AM CN3 Health-Related Quality of Life Assessments Predict Relapse or Death in Patients with Newly Diagnosed
Multiple Myeloma (MM): Results from the Connect® MM Registry
Wagner I1, Durie BG2, Jagannath S3, Narang M4, Terebelo HR5, Gasparetto C6, Toomey K7, Hardin JW8, Kitali A9, Yue L9, Agarwal
A9, Srinivasan S9, Flick ED9, Rifkin RM10, Abonour R11, 1Wake Forest University School of Medicine, Winston-Salem, NC, USA,
2
Cedars-Sinai Samuel Oschin Cancer Institute, Los Angeles, CA, USA, 3Mount Sinai Hospital, New York, NY, USA, 4Maryland
Oncology Hematology, Columbia, MD, USA, 5Providence Hospital and Medical Center, Southfield, MI, USA, 6Duke Cancer
Institute, Durham, NC, USA, 7Steeplechase Cancer Center, Somerville, NJ, USA, 8University of South Carolina, Columbia, SC,
USA, 9Celgene Corporation, Summit, NJ, USA, 10US Oncology Research and Rocky Mountain Cancer Centers, Denver, CO,
USA, 11Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA
11:45AM-12:00PM CN4 Projecting Overall Survival (OS) with Immuno-Oncology (IO) Treatments: Application of Alternative Approaches
in Metastatic Merkel Cell Carcinoma (MMCC)
Proskorovsky I1, Lanitis T2, Ambavane A2, Hunger M3, Bharmal M4, Zheng Y5, Phatak H5, 1Evidera, Montreal, QC, Canada,
2
Evidera, London, UK, 3Mapi, an ICON plc Company, Munich, Germany, 4Merck KGaA, Darmstadt, Germany, 5EMD Serono Inc.,
Rockland, MA, USA
P8: Cardiovascular Studies Room 310 (Level 300)

Moderator: Jay Lin, PhD, MBA, Novosys Health, Green Brook, NJ, USA
11:00AM-11:15AM CV1 Non-Inferiority Clinical Trial Design, Drug Approval, and Implications for Clinicians in Prescribing Oral
Anticoagulants
Choi YC1, Vo TN1, Carlson AM2, 1University of Minnesota, Minneapolis, MN, USA, 2Data Intelligence Consultants, LLC, Eden
Prairie, MN, USA
26 #ISPORBaltimore
Tuesday May 22
11:15AM-11:30AM CV2 Secondary Prevention Using Cholesterol-Lowering Medications in Patients Meeting New Treatment Guidelines:
A Retrospective Cohort Analysis
Han X1, McCombs JS1, Fox DS1, Chu M1, Dougherty JS2, 1University of Southern California, Los Angeles, CA, USA, 2PhRMA,
Washington, DC, USA
11:30AM-11:45AM CV3 Comparative Effectiveness of Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation
Done N1, Li D1, Woolley A2, Rose AJ3, Prentice JC1, 1Veterans Health Administration, Boston, MA, USA, 2Bouve College of Health
Sciences, Boston, MA, USA, 3RAND Corporation, Boston, MA, USA
11:45AM-12:00PM CV4 Adherence to Self-Care Recommendations and Associated Factors Among Adult Heart Failure Patients at
Gondar University Referral Hospital, Northwest Ethiopia.
Seid MA
University of Gondar, Gondar, Ethiopia
12:00PM-2:15PM LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION III Halls B-D (Level 100)
12:30PM-12:45PM ISPOR GENERAL SPECIAL INTEREST GROUP OPEN MEETING Room 307 (Level 300)
ISPOR members are invited to attend an open meeting to learn about the new structure and formation of Special Interest
Groups (SIGs) at ISPOR. Information will be available about new SIGs that are in the process of forming.

Advancements in Methods of Survival Benefit Estimation for Novel Oncology Drugs and Their Applications in ICER
Reviews 309 (Level 300)
Sponsored by Analysis Group
Moderator: Eric Q. Wu, PhD, Analysis Group, Inc., Bosotn, MA, USA
Speakers: Scott D. Ramsey, MD, PhD, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA,
USA; Daniel A. Ollendorf, PhD, Institute for Clinical and Economic Review, Boston, MA, USA; Jipan Xie, MD, PhD, Analysis
Group, Inc., New York, NY, USA
12:45PM-2:00PM ISPOR PATIENT-RESEARCH SPECIAL INTEREST GROUPS OPEN MEETING Room 307 (Level 300)
ISPOR is holding an open meeting to discuss three similar, but different topics related to the patient initiatives at ISPOR.
Leadership group members of each of the identified SIGs will discuss the main goal and objectives of their SIG. The group
will discuss how each of these topics are related, identify gaps, and generate ideas for each of the groups to focus on.
Participants are asked to bring their suggestions and topics that are relevant and would like to see the SIGs develop. This will
include Patient Reported Outcomes/Clinical Outcomes Assessment.
12:45PM-2:00PM ISPOR BIOSIMILAR SPECIAL INTEREST GROUP OPEN MEETING Room 308 (Level 300)
ISPOR members interested in or working with biosimilars are welcome to attend this open meeting to discuss the formation
of the ISPOR Biosimilar SIG, explore the issues within this space, and identify projects to address them.
12:45PM-2:00PM ISPOR MEDICAL DEVICES AND DIAGNOSTICS SPECIAL INTEREST GROUP OPEN MEETING Room 310 (Level 300)
ISPOR members interested in medical devices and diagnostics are encouraged to attend this meeting to identify SIG
leadership and suggest topics and projects for the group to develop.
12:45PM-2:00PM ISPOR NUTRITION ECONOMICS SPECIAL INTEREST GROUP OPEN MEETING Room 315 (Level 300)
ISPOR members interested in nutrition economics or medical nutrition are invited to attend this meeting to discuss the work
of the group to date and identify new topics for the leadership group to address.
1:00PM-2:00PM POSTER AUTHOR DISCUSSION HOUR - SESSION III Halls B-D (Level 100)
1:15PM-2:00PM ISPOR GENERAL BUSINESS MEETING Room 316-317 (Level 300)

Attendees are invited to attend ISPOR’s General Business Meeting, the official business meeting of the Society. Members will
learn about ISPOR’s recent accomplishments and plans for the future and have the opportunity to meet Board members.

IP10: Prior Authorization Policies for Managing Specialty Drug Spending in the United States: Can We Strike a
Balance Between Appropriate Utilization and Appropriate Access? Ballroom III (Level 400)
Moderator: Jalpa A. Doshi, PhD, University of Pennsylvania, Philadelphia, PA, USA
Panelists: Steven Miller, MD, MBA, Express Scripts, St. Louis, MO, USA; Cat Davis Ahmed, MBA, The FH Foundation,
Pasadena, CA, USA; Seth J. Baum, MD, Florida Atlantic University and Excel Medical Clinical Trials, Boca Raton, FL, USA
www.ispor.org 27
Tuesday May 22
IP11: “Making Medicines Affordable: A National Imperative” – Reflections on the National Academies Report
(Invited Issue Panel) Ballroom I (Level 400)
Moderator: Guru Madhavan, PhD, MBA, National Academies of Science, Engineering, and Medicine, Washington, DC, USA
Panelists: Norman Augustine, MS, Lockheed Martin Corporation, Bethesda, MD, USA; Charles E. Phelps, PhD, MBA,
University of Rochester, Rochester, NY, USA; Stacie B. Dusetzina, PhD, Vanderbilt University Medical Center, Nashville, TN,
USA; Robert W. Dubois, MD, PhD, National Pharmaceutical Council, Washington, DC, USA
W12: Complex Real-World Evidence: Networked and Missing Data Ballroom II (Level 400)
Discussion Leaders: Laura Hatfield, PhD, Harvard Medical School, Boston, MA, USA; Sherri Rose, PhD, Harvard Medical
School, Boston, MA, USA; Alisa Stephens-Shields, PhD, University of Pennsylvania, Perelman School of Medicine,
Philadelphia, PA, USA; Amanda Mejia, PhD, Indiana University, Bloomington, IN, USA
3:15PM-3:45PM BREAK & EXHIBITS VIEWING
3:30PM-7:30PM RESEARCH POSTER PRESENTATIONS - SESSION IV Halls B-D (Level 100)

IP12: What Research Should Be Undertaken to Support Decisions Regarding the Value of Curing or Eradicating
Disease? Ballroom I (Level 400)
Moderator: John Watkins, PharmD, MPH, Premera Blue Cross, Mountlake Terrace, WA, USA
Panelists: Mark Sculpher, PhD, University of York, York, UK; Steven D. Pearson, MD, MSc, FRCP, Institute for Clinical and
Economic Review, Boston, MA, USA; Carleigh B Krubiner, PhD, Johns Hopkins University, Baltimore, MD, USA
IP13: Surrogate Outcomes in Oncology: How Can They Be Used to Predict Overall Survival in Clinical Practice
and Payer Decision Making? Hall A (Level 100)
Moderator: Jipan Xie, MD, PhD, Analysis Group, Inc., Los Angeles, CA, USA
Panelists: Yiduo Zhang, PhD, AstraZeneca, Gaithersburg, MD, USA; Russell Hales, MD, The Johns Hopkins Sidney Kimmel
Comprehensive Cancer Center, Baltimore, MD, USA; Louis P. Garrison, PhD, University of Washington, Seattle, WA, USA
IP14: Does Measuring the Economic Value of Clinical Genomic Sequencing Require New Methodological
Approaches? Room 310 (Level 300)
Moderator: Kathryn A. Phillips, PhD, University of California – San Francisco, San Francisco, CA, USA
Panelists: Deborah A. Marshall, PhD, University of Calgary, Calgary, AB, Canada; Dean A. Regier, PhD, Canadian Centre for
Applied Research in Cancer Control (ARCC), British Columbia Cancer Agency, Vancouver, BC, Canada; Sarah Wordsworth,
PhD, University of Oxford, Oxford, UK
W13: What Is Patient-Centered and Fit-For-Purpose Patient Preference Information? Ballroom III (Level 400)
Discussion Leaders: Stephanie Christopher, MA, Medical Device Innovation Consortium, Arlington, VA, USA; Anindita Saha,
BSE, US Food & Drug Administration, Silver Spring, MD, USA; A. Brett Hauber, PhD, RTI Health Solutions, Research Triangle
Park, NC, USA; Margaret Sheehan, JD, The Michael J. Fox Foundation for Parkinson’s Research, New York, NY, USA
W14: Network Meta-Analysis for Various Study Designs: Stepping Outside the Randomized Controlled Trials
Comfort Zone into the Real World Ballroom IV (Level 400)
Discussion Leaders: Christopher Schmid, PhD, Brown University, Providence, RI, USA; Ashley Pitcher, BSc, DPhil, IQVIA,
London, UK; Andreas Karabis, PhD, IQVIA, Amsterdam, The Netherlands
P9: Health Technology Assessment Studies Room 309 (Level 300)

Moderator: Andrew Briggs, DPhil, University of Glasgow, Glasgow, Scotland
3:45PM-4:00PM HT1 Similarities and Differences in European HTA Evidence Requirements: One for All or One for None?
Mordin M1, Fernandez MM2, Pearson I3, Copley-Merriman C1, McBride D3, 1RTI Health Solutions, Ann Arbor, MI, USA, 2RTI
Health Solutions, Research Triangle Park, NC, USA, 3RTI Health Solutions, Manchester, UK
4:00PM-4:15PM HT2 A Holistic Approach to Evaluate the Cost-Effectiveness of Pembrolizumab with Multiple Indications: A Norway-
Based Example
Wu E1, Pellissier J1, Kvamme M2, Irgens K2, 1Merck, North Wales, PA, USA, 2MSD Norge A/S, Drammen, Norway
4:15PM-4:30PM HT3 Using Real-World Evidence for Health Technology Assessment Submissions: Lessons and Insights from Review
of NICE’s Technology Assessment Reports (2016-2017)
Aggarwal S1, Topaloglu O1, Kumar S2, 1NOVEL Health Strategies, Chevy Chase, MD, USA, 2Institute for Global Policy,
Washington, DC, USA
4:30PM-4:45PM HT4 Health Techonolgy Assessment (HTA) Agencies Consideration of Real World Evidence (RWE)
Jao R1, Jaksa A1, Pontynen A1, Wang X2, 1Context Matters, New York, NY, USA, 2Celgene Corporation, Summit, NJ, USA
28 #ISPORBaltimore
Tuesday May 22
P10: Healthcare Utilization and Outcomes Studies Ballroom II (Level 400)
Moderator: Ebere Onukwugha, MS, PhD , University of Maryland School of Pharmacy, Baltimore, MD, USA
3:45PM-4:00PM HU1 Annual Change in Controlled Substance Opioid Prescribing and Concomitant Medications from an Urban
Academic Emergency Department from 2011 – 2016
Voelker J1, Crawford A1, Sabonjian M2, Maio V3, Mammen P2, 1Jefferson College of Population Health at Thomas Jefferson
University, Philadelphia, PA, USA, 2Thomas Jefferson University Hospital, Philadelphia, PA, USA, 3Thomas Jefferson University,
Philadelphia, PA, USA
4:00PM-4:15PM HU2 Cognitive Decline with Anticholinergic Medication Use Among Elderly Nursing Home Residents with Depression
Aparasu RR1, Chatterjee S2, Johnson ML3, Chen H3, Carnahan R4, 1Department of Pharmaceutical Health Outcomes and
Policy, Houston, TX, USA, 2Novartis Healthcare Pvt Ltd, Hyderabad, India, 3College of Pharmacy, University of Houston,
Houston, TX, USA, 4University of Iowa, Iowa City, IA, USA
4:15PM-4:30PM HU3 Initiation of Psychotropic Prescriptions Without a Psychiatric Diagnosis in US Adults
Rhee TG1, Rosenheck RA2, 1Yale University School of Medicine, New Haven, CT, USA, 2Yale University School of Medicine,
West Haven, CT, USA
4:30PM-4:45PM HU4 The Use of Machine Learning to Boost Identification of Atrial Fibrillation and Increase Appropriate Utilization
of Anticoagulant Drugs
Hertzberg J, Forni A, Optum, Minnetonka, MN, USA

IP15: How Can We Address the Current Challenges in Value Assessment? Hall A (Level 100)
Moderator: Sachin Kamal-Bahl, PhD, Pfizer, Inc., New York, NY, USA
Panelists: Josh J. Carlson, MPH, PhD, University of Washington, Seattle, WA, USA; Shelby D. Reed, PhD, RPh, Duke Clinical
Research Institute, Durham, NC, USA; Gillian D. Sanders Schmidler, PhD, Duke University, Durham, NC, USA
IP16: In the Electronic Health Record Era, Do We Still Need Clinical Registries? Ballroom IV (Level 400)
Moderator: Lisa M. Wruck, PhD, Duke Clinical Research Institute, Durham, NC, USA
Panelists: Sharon Hensley Alford, PhD, IBM Watson Health, Cambridge, MA, USA; Marc Berger, MD, Self Employed, New
York, NY, USA; Matthew T. Roe, MD, MHS, Duke Clinical Research Institute, Durham, NC, USA
IP17: Has the Time Come to Replace Randomized Controlled Trials with Real-World Data – A Case of Medical
Devices? Ballroom II (Level 400)
Moderator: Rok Hren, PhD, MSc, Siemens Healthcare Diagnostics GmbH, Vienna, Austria and Univeristy of Ljubljana,
Ljubljana, Slovenia
Panelists: Katarzyna Kolasa, PhD, Kozminski University, Warszawa, Poland; Rosanna Tarricone, SDA Bocconi School of
Management, Milan, Italy; Cynthia Iglesias, PhD, University of York, York, UK
W15: Patient Involvement Throughout the Stages of Patient-Reported Outcome Development and Clinical Trial
Implementation Ballroom III (Level 400)
Discussion Leaders: Sarah L. Knight, BSc (hons), MSc, DRG Abacus, Bicester, UK; Helen Kitchen, MSc, DRG Abacus,
Manchester, UK; Ann Hartry, PhD, Lundbeck, Deerfield, IL, USA; Cindy Coney, MEd, BSc, Monarch Training and Consulting,
Tampa, FL, USA
W16: Choosing How to Choose: Collective Decision Making in Healthcare Organizations Ballroom I (Level 400)
Discussion Leaders: Charles E. Phelps, PhD, MBA, University of Rochester, Rochester, NY, USA; Guru Madhavan, PhD, MBA,
National Academies of Science, Engineering, and Medicine, Washington, DC, USA
P11: Medication Adherence Studies Room 309 (Level 300)

Moderator: Julia Slejko, PhD, BA, University of Maryland School of Pharmacy, Baltimore, MD, USA
5:00PM-5:15PM AD1 The Association Between Anti-Epileptic Drug Adherence to Sodium Channel Blockers and Health-Related
Quality of Life: Analysis of US Survey Data from Patients with Epilepsy
Lee LK1, Rajagopalan K2, 1Kantar Health, San Mateo, CA, USA, 2Sunovion Pharmaceuticals Inc., Marlborough, MA, USA
5:15PM-5:30PM AD2 Modified Drug Adherence Work-Up (M-Draw) Tool in Patients with Diabetes at Veterans Affairs Health System:
Tool Validation and Preliminary Result
Lee S1, Gogineni H1, Bae-Shaaw Y2, Worley M3, Law A1, 1Western University of Health Sciences, Pomona, CA, USA, 2University
of Southern California, Los Angeles, CA, USA, 3The Ohio State University, Columbus, OH, USA
5:30PM-5:45PM AD3 Adherence Issues in Fibromyalgia: How Can Acceptance Measurement Help Understanding Patients’ Concerns
and Working on Solutions?
Wiederkehr S1, de Bock E1, Chekroun M2, Arnould B1, 1Mapi, An ICON plc Company, Patient-Centered Outcomes, Lyon,
France, 2Carenity, Paris, France
5:45PM-6:00PM AD4 Discontinuation, Switching and Restarting Among Migraine Patients Initiating Prophylaxis
Bonafede MM1, Wilson KL1, Xue F2, Chia VM2, Porter JK3, Desai P2, 1Truven Health Analytics, an IBM Company, Cambridge,
MA, USA, 2Amgen Inc., Thousand Oaks, CA, USA, 3Amgen (Europe) GmbH, Zug, Switzerland
www.ispor.org 29
Tuesday May 22
P12: Cost-Effectiveness Antiviral Studies Room 310 (Level 300)
Moderator: Sonya J. Snedecor, PhD, Pharmerit International, Bethesda, MD, USA
5:00PM-5:15PM AV1 Cost-Effectiveness of Staged Direct-Acting Antiviral Treatment Policies in an Integrated Healthcare System
Karmarkar T1, Gaskin DJ1, Rodriguez CV2, Padula WV1, 1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD,
USA, 2Kaiser Permanente, Rockville, MD, USA
5:15PM-5:30PM AV2 Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimise
Treatment Duration in Genotype 1 Non-Cirrhotic Treatment-Naïve Patients with Chronic Hepatitis C Virus
Fawsitt CG1, Vickerman P1, Cooke G2, Welton NJ1, 1University of Bristol, Bristol, UK, 2Imperial College London, London, UK
5:30PM-5:45PM AV3 Dolutegravir and Rilpivirine to Treat Virologically Suppressed Adults Living with HIV-1: A Canadian Cost-Utility Analysis
Arthurs E1, Ward T2, Darlington O2, Sugrue D2, Martin AA3, Cartier SE4, Lee A4, Becker DL4, Punekar YS5, McEwan P2
1
GSK, Mississauga, ON, Canada, 2Health Economics & Outcomes Research Ltd, Cardiff, UK, 3GSK, Uxbridge, UK, 4Optum,
Burlington, ON, Canada, 5ViiV Healthcare, Brentford, Middlesex, UK
5:45PM-6:00PM AV4 Cost-Effectiveness Analysis of Universal vs Targeted Human Immunodeficiency Virus (HIV) Screening
Approaches to Identify New HIV Diagnoses in the Emergency Department (ED)
Batista AE1, Bartolome L1, Nelson F2, Maio V1, Mammen P2
1
Thomas Jefferson University, Philadelphia, PA, USA, 2Thomas Jefferson University Hospital, Philadelphia, PA, USA
6:00PM-7:45PM EXHIBITORS’ WINE & CHEESE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION IV
Halls B-D (Level 100)

F6: Value of Information Analysis for Research Decisions Emerging Good Practices: Final Recommendations
Ballroom IV (Level 400)
Presented by the ISPOR VOI Emerging Good Practices Task Force
Moderator: Rachael Fleurence, PhD, Medical Device Innovation Consortium (MDIC), Arlington, VA, USA
Speakers: Lotte Steuten, PhD, MSc, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Anirban Basu, PhD,
University of Washington, Seattle, WA, USA; Gillian D. Sanders Schmidler, PhD, Duke University, Durham, NC, USA;
James F. Murray, PhD, Eli Lilly and Company, Carmel, IN, USA
F7: Enabling ISPOR Member and Patient Advocacy Group Research Collaboration: A Volunteer Plan
Presented by the ISPOR Patient-Research Matchmaking Group
Moderator: Richard J. Willke, PhD, ISPOR, Lawrenceville, NJ, USA
Speakers: Laura T. Pizzi, PharmD, MPH, Rutgers University, Piscataway, NJ, USA; Jason Harris, BA, National Health Council,
Washington, DC, USA; Brian Ung, PharmD, MS, Celgene Corporation, Summit, NJ, USA
F8: Real-World Evidence and Local Evidence Generation: How Should It Be Approached in Asia Pacific?
Ballroom II (Level 400)
Presented by the ISPOR Asia Consortium HTA Agencies, Healthcare Policymakers & Payers Committee
Moderator: Jitendar Sharma, PhD, Andhra Pradesh MedTech Zone Limited, Andhra Pradesh, India
Speakers: Sukyeong Kim, PhD, National Evidence-Based Healthcare Collaborating Agency, Seoul, Republic of South Korea;
Makoto Kobayashi, PhD, MEng, CRECON Medical Assessment Inc., Tokyo, Japan; Chee-Jen Chang, PhD, Chang Gung
University, Taoyuan City, Taiwan; Jianwei Xuan, MD, PhD, Health Economic Research Institute, School of Pharmacy, Sun
Yat-Sen University, Guangzhou, China
F9: New Developments of Value-Based Payment Arrangements and Value Demonstration in Latin American
Health Systems Ballroom III (Level 400)
Presented by the LA Consortium Technology Producers Committee
Moderator: Juan Carlos Alandete Manotas, MD, MSc, MPH, Bayer, Whippany, NJ, USA
Speakers: Louis Garrison, PhD, University of Washington, Seattle, WA, USA; Ramiro E. Gilardino, MD, MSc, ISPOR,
Lawrenceville, NJ, USA; Boxiong Tang, MD, PhD, Teva Pharmaceutical, Frazer, PA, USA
6:30PM-7:30PM POSTER AUTHOR DISCUSSION HOUR - SESSION IV Halls B-D (Level 100)
9:00PM-11:00PM ISPOR SOCIAL EVENT Tin Roof Baltimore

Join us for an evening of networking, light bar bites, and live music at the ISPOR social event at Tin Roof Baltimore. Known
as the “Live Music Joint, where Everybody is Somebody,” Tin Roof offers a fun, inviting, eclectic, laid-back atmosphere.
Conveniently located in Baltimore’s popular Power Plant Live and only 1 block away from the world famous Downtown Inner
Harbor. So whether you are coming to dance or to grab a drink, this is the perfect opportunity to reconnect with your ISPOR
peers! Separate registration required.
30 #ISPORBaltimore
< advertisement >
www.ispor.org 31
< advertisement >
32 #ISPORBaltimore
Wednesday May 23
7:15AM-8:15AM EDUCATIONAL SYMPOSIUM Room 309 (Level 300)

Bridging the Gap Between Retrospective Data and Registries: Where Do We Go from Here?
Sponsored by Ipsos Healthcare
Moderator: Christopher M Blanchette, PhD, MBA, Ipsos Healthcare, New York, NY, USA
Speakers: Jeffrey Vernice, PhD, MBA, MS, Horizon Blue Cross Blue Shield of New Jersey, Newark, NJ, USA; Elaine B. Yu,
PharmD, MS, Genentech, Inc., South San Fransisco, CA, USA; Joshua M Noone, PhD, Ipsos Healthcare, New York, NY, USA;
Emily Zacherle, MS, Ipsos Healthcare, New York, NY, USA
8:30AM-1:30PM RESEARCH POSTER PRESENTATIONS - SESSION V Halls B-D (Level 100)
8:30AM-9:30AM BREAKOUT SESSION

IP18: When Research Questions Collide: How Much Is the United States Actually Spending on Drugs?
Moderator: Michael Kleinrock, MA, IQVIA Institute for Human Data Science, Plymouth Meeting, PA, USA
Panelists: Sean Keehan, MA, Centers for Medicare and Medicaid Services, Baltimore, MD, USA; Cynthia Cox, MPH, Kaiser
Family Foundation, Washington, DC, USA; Sara Sadownik, MSc, Massachusetts Health Policy Commission, Boston, MA, USA
IP19: Value Assessment Frameworks in an Era of Personalized Medicine: Shared Objectives or Irreconcilable
Differences? Ballroom II (Level 400)
Moderator: Kristen Migliaccio-Walle, BS, Xcenda, LLC, Palm Harbor, FL, USA
Panelists: Donna Cryer, JD, Global Liver Institute, Washington, DC, USA; Daniel A Ollendorf, PhD, Institute for Clinical and
Economic Review, Boston, MA, USA; Robert W Dubois, MD, PhD, National Pharmaceutical Council, Washington, DC, USA
W17: Do Cutting-Edge One-Time Treatments Need Equally Innovative-, Outcomes-, or Annuity-Based Payment
Models? Ballroom III (Level 400)
Discussion Leaders: Mark Chalmers, PhD, CBPartners, London, UK; Andrew Gould, MS, CBPartners, New York, NY, USA;
Maximilian Hunt, BSc, CBPartners, New York, NY, USA; Omar Ali, BSc, DipClinPharm, MRPharmS, ACPP, NICE,
London, UK
W18: Open Source Software for Building Health Economic Models Ballroom IV (Level 400)
Discussion Leaders: Joseph F. Levy, BS, University of Maryland School of Pharmacy, Baltimore, MD, USA; Fernando Alarid-
Escudero, PhD, University of Minnesota, Minneapolis, MN, USA; Erik J. Dasbach, PhD, Merck & Co. Inc., Kenilworth, NJ, USA
P13: Conceptual Papers Room 309 (Level 300)

Moderator: Karen Rascati, RPh, PhD, The University of Texas College of Pharmacy, Austin, TX, USA
8:30AM-8:45AM CP1 An Analytical Framework for Economic Evaluation of Interventions with Effects on Multiple Outcomes, Costs
Falling on Different Budgets, and Involving More Than One Decision Maker
Griffin S1, Walker S2, Sculpher M1, Asaria M2, 1University of York, York, UK, 2University of York, Heslington, York, UK
www.ispor.org 33
Wednesday May 23
8:45AM-9:00AM CP2 Graphical Probabilistic Models for Risk Prediction and Decision Making Using Real-World Data: A Developing
Tool for the Era of Precision Medicine
Arora P1, Boyne DJ2, Druzdzel MJ3, 1Lighthouse Outcomes, Toronto, ON, Canada, 2University of Calgary, Calgary, ON, Canada,
3
University of Pittsburgh, Pittsburgh, PA, USA
9:00AM-9:15AM CP3 Assessment-Time Bias: Statistical Approaches to Adjusting for Between-Trial Differences in the Schedule of
Assessment for Disease Progression in Immuno-Oncology Trials
Kapetanakis V1, Schlichting M2, Stevens JW3, Prawitz T1, Kearney M4, Phatak H5, Benedict A6, Bharmal M4, 1Evidera, London,
UK, 2Global Biostatistics and Epidemiology, Merck KGaA, Darmstadt, Germany, 3Reader in Decision Science, University of
Sheffield, Sheffield, UK, 4Global Evidence & Value Development, Merck KGaA, Darmstadt, Germany, 5EMD Serono, Rockland,
MA, USA, 6Evidera, Budapest, Hungary
9:15AM-9:30AM CP4 Budget Impact Analysis with Simultaneous Multiple Market Entrants: Static versus Dynamic Baseline
Market Shares
O’Day K, Meyer K, Xcenda, Palm Harbor, FL, USA
P14: Healthcare Resource Use and Expenditure Studies Room 310 (Level 300)
Moderator: Brian Rittenhouse, Massachusetts College of Pharmacy and Health Sciences (MCPHS) University, Boston,
MA, USA
8:30AM-8:45AM HE1 Effect of a Provider-Focused Asthma Care Quality Improvement Program on Patient-Level Asthma-Related
Healthcare Costs
Rojanasarot S, Carlson AM, St. Peter WL, Schommer JC, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA
8:45AM-9:00AM HE2 Healthcare Costs in Diabetes: The Role of Comorbidity Type
Lin P1, Pope E1, Zhou FL2, 1Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health
Policy Studies,Tufts Medical Center, Boston, MA, USA, 2Sanofi, Bridgewater, NJ, USA
9:00AM-9:15AM HE3 A Tale of Two Universal Health Insurance Schemes in One Country: Horizontal Inequality of Government
Medical and Pharmaceutical Benefits for Australian Children
Huang L, Clarke P, Dalziel K, The University of Melbourne, Melbourne, Australia
9:15AM-9:30AM HE4 Real-World Analysis of Treatment Patterns and Long-Term Effectiveness Among Patients with Advanced
Neuroendocrine Tumors of Lung Origin (LUNG Net): A Multicenter Study
Dasari A1, Bergsland EK2, Benson AB3, Cai B4, Huynh L5, Totev T5, Shea J5, Duh MS5, Neary MP4, Kulke MH6, 1University of Texas
MD Anderson Cancer Center, Houston, TX, USA, 2UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA,
USA, 3Northwestern University Feinberg School of Medicine, Chicago, IL, USA, 4Novartis Pharmaceuticals Corporation, East
Hanover, NJ, USA, 5Analysis Group, Inc., Boston, MA, USA, 6Dana-Farber Cancer Institute, Boston, MA, USA
9:30AM-10:00AM BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION V Halls B-D (Level 100)
10:00AM-11:45AM WELCOME & THIRD PLENARY SESSION Hall A (Level 100)

Welcome from ISPOR President
ISPOR Service Awards
ISPOR Student Awards
Zeba M. Khan, MS, RPh, PhD, Celgene Corporation, Summit, NJ, USA
PhRMA Foundation Awards
Nancy S. Santanello, MD, MS, FISPE, Independent Research Consultant, New Hope, PA, USA
ISPOR 2019 Meeting Announcement
Third Plenary Session: Examining the Role of Patient Preferences to Inform Regulatory Decisions
Moderator: Shelby D. Reed, PhD, RPh, Duke University, Durham, NC, USA
Speakers: Bennett Levitan, MD, PhD, Janssen Research & Development, Titusville, NJ, USA; Matt Reaney, FRSPH, MSc,
Sanofi, Guildford, Surrey, UK; Jeff Shuren, MD, JD, U.S. Food and Drug Administration, Silver Spring, MD, USA
11:45AM-1:45PM LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION V Halls B-D (Level 100)
34 #ISPORBaltimore
Wednesday May 23
12:30PM-1:30PM POSTER AUTHOR DISCUSSION HOUR - SESSION V Halls B-D (Level 100)

IP20: The Patient Perspective and Value Assessment: Easy to Identify the Need, Hard to Agree on the Solution
Moderator: Mike Ciarametaro, MBA, National Pharmaceutical Council, Washington, DC, USA
Panelists: Ilene L. Hollin, PhD, MPH, National Pharmaceutical Council and University of Southern California Schaeffer Center
for Health Policy and Economics, Washington, DC, USA; David Wamble, MS, MBA, RTI Health Solutions, Durham, NC, USA;
Josh Seidman, PhD, MHS, Avalere, Washington, DC, USA
IP21: Is Artificial Intelligence the Next Big Thing in Healthcare Decision Making? Ballroom II (Level 400)
Moderator: Santiago Ernesto Herran, MD, Bayer andina, Bogota, Colombia
Panelists: Rafael Alfonso Cristancho, MD, MSc, PhD, GlaxoSmithKline, Collegeville, PA, USA; Juan-David Rueda, MD, MS,
University of Maryland School of Pharmacy, Baltimore, MD, USA; Carrie Savage Bennette, PhD, MPH, Flatiron, NY, NY, USA
W19: Medical Device Real-World Evidence for Beginners: A Primer Room 310 (Level 300)
Discussion Leaders: Stephen S Johnston, MA, Johnson & Johnson, Inc., New Brunswick, NJ, USA; Joshua Gagne, PharmD,
ScD, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Frank R. Ernst, PharmD, MS, CTI Clinical Trial and
Consulting Services, Covington, KY, USA; Abhishek S Chitnis, PhD, MPharm, Johnson & Johnson, New Brunswick, NJ, USA
W20: Fixing the Tower of Babel: Establishing a Common Metric for Patient-Reported Outcome Measures
Ballroom IV (Level 400)
Discussion Leaders: Jakob B. Bjorner, MD, PhD, Optum Patient Insights, Johnston, RI, USA; Benjamin D. Schalet, PhD,
Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Felix Fischer, PhD, Charité Universitätsmedizin
Berlin, Berlin, Germany; Ian Kudel, PhD, Optum Patient Insights, Johnston, RI, USA
W21: Principles of Effective Machine Learning Applications in Real World Evidence Room 309 (Level 300)
Discussion Leaders: Andrew Cox, PhD, Evidera, London, UK; Sreeram Ramagopalan, PhD, Bristol-Myers Squibb
Pharmaceuticals Ltd, Uxbridge, UK; Gorana Capkun-Niggli, PhD, Novartis Pharma AG, Basel, Switzerland; David J. Vanness,
PhD, University of Wisconsin-Madison, Madison, WI, USA
P15: Utility and Patient Preference Studies Ballroom III (Level 400)
Moderator: John E. Brazier, PhD, FMedSci, University of Sheffield, Sheffield, UK
1:45PM-2:00PM PP1 Patient Preferences for Health States Following Alternative Management Options for Ductal Carcinoma in Situ
Campbell BM1, Yang J2, Gonzalez JM2, Reed SD2, Havrilesky L3, Johnson FR2, Hwang ES3, 1Duke University School of Medicine,
Durham, NC, USA, 2Duke Clinical Research Institute, Durham, NC, USA, 3Duke Cancer Institute, Durham, NC, USA
2:00PM-2:15PM PP2 Choice Defines QALYs: A US Valuation of the EQ-5D-5L
Craig BM1, Rand K2, 1University of South Florida, Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA,
2
University of Oslo, Oslo, Norway
2:15PM-2:30PM PP3 Estimating the Health State Utility of Patients with Her2– GBRCA+ Metastatic Breast Cancer Treated with
Olaparib or Chemotherapy Via a Mapping Analysis of Eortc QLQ-C30 Data Collected in the Olympiad Clinical Trial
Robson M1, Hettle R2, Degboe A3, Saunders O4, Cain T4, Kilvert H4, Johnson H4, 1Memorial Sloan Kettering Cancer Center,
New York, NY, USA, 2AstraZeneca, Cambridge, UK, 3AstraZeneca, Gaithersburg, MD, USA, 4Bresmed Ltd, Sheffield, UK
2:30PM-2:45PM PP4 Consumer Preferences for Precision Medicine Technologies: Evidence from a Discrete Choice Experiment
Regier DA1, Veenstra DL2, Basu A3, Saha J2, Carlson JJ3, 1BC Cancer/University of British Columbia, Vancouver, BC, Canada,
2
Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA,
3
University of Washington, Seattle, WA, USA
2:45PM-3:00PM BREAK

IP22: Challenges and Opportunities in the Use of Real-World Evidence for Regulatory Decision Making for in
Vitro Diagnostics Ballroom I (Level 400)
Moderator: Tyler J. O’Neill, DVM, MSc, PhD, Roche Diagnostics, Pleasanton, CA, USA
Panelists: Michael S. Waters, PhD, U.S. Food and Drug Administration, Silver Spring, MD, USA; Brad Spring, BS, BD Life
Sciences, Sparks, MD, USA; Asif Jan, PhD, Roche Diagnostics, Pleasanton, CA, USA
www.ispor.org 35
Wednesday May 23
IP23: Estimating Sample Size for Qualitative Research in Clinical Outcome Assessment Research: One Size Does
Not Fit All! Ballroom II (Level 400)
Moderator: Helen Kitchen, MSc, DRG Abacus, Manchester, UK
Panelists: Kathryn Lasch, PhD, Pharmerit International, Newton, MA, USA; Helen Doll, PhD, Clinical Outcomes Solutions,
Folkestone, UK; Katy Benjamin, PhD, Abbvie Inc, Chicago, IL, USA
W22: The Medium Is the Message: Using Interactive Graphics to Effectively Communicate Health Economics and
Outcomes Research Findings Ballroom III (Level 400)
Discussion Leaders: Shelagh M Szabo, MSc, Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada;
Ross Tsuyuki, MSc PharmD, University of Alberta, Edmonton, AB, Canada; Andrew Lloyd, DPhil, Acaster Lloyd Consulting
Ltd., London, UK; Bonnie M Donato, PhD, Alexion Pharmaceuticals, Inc, New Haven, CT, USA
W23: Estimating the Cost of Adverse Events in Economic Models: A Discussion of Real-World Data versus
Treatment Guidelines Based Methodologies Ballroom IV (Level 400)
Discussion Leaders: William Wong, PharmD, MS, Genentech, Inc., South San Francisco, CA, USA; Martin Cloutier, MSc,
Analysis Group, Inc., Montreal, QC, Canada; Josh J. Carlson, MPH, PhD, University of Washington, Seattle, WA, USA
P16: Infectious Disease and Respiratory Studies Room 309 (Level 300)
Moderator: Fadia T. Shaya, PhD, MPH, Baltimore, MD, USA
3:00PM-3:15PM IN1 Using Electronic Health Records to Examine HPV Vaccine Initiation and Completion Rates
Yu J, Buikema AR, Togun A, Optum, Eden Prairie, MN, USA
3:15PM-3:30PM IN2 Long-Term Health Benefit of Ibalizumab in the Treatment of Adults with Multidrug-Resistant HIV-1 Infection
Brogan AJ1, Talbird SE2, Davis AE2, La EM2, Miao Z3, Lewis S4, 1RTI Health Solutions, Didsbury, Manchester, UK, 2RTI Health
Solutions, Research Triangle Park, NC, USA, 3Theratechnologies Inc., Montréal, QC, Canada, 4TaiMed Biologics, Irvine, CA, USA
3:30PM-3:45PM IN3 Incidence of Hepatocellular Carcinoma and Extrahepatic Cancers Among HCV-Infected Patients in the Era of
Direct-Acting Antivirals
Wang W1, Lo Re III V2, Xiao H1, Brown J1, Yi G1, Park H1, 1University of Florida, Gainesville, FL, USA, 2University of Pennsylvania,
Philadelphia, PA, USA
3:45PM-4:00PM IN4 Estimating the Current Cost of Endoscopic Sinus Surgery in the Us – A Claims-Based Approach
Velez FF1, Sacks H1, Messina J1, Kozma CM2, Malone D3, Mahmoud R1, 1OptiNose US, Inc., Yardley, PA, USA, 2CK Consulting
Associates, LLC, Saint Helena Island, SC, USA, 3University of Arizona, Tucson, AZ, USA
P17: Neurological Conditions Studies Room 310 (Level 300)

Moderator: Michael T. Halpern, MD, PhD, MPH, Temple University College of Public Health, Philadelphia, PA, USA
3:00PM-3:15PM ND1 Use of Disease Modifying Agents in Patients with Multiple Sclerosis: Analysis of Ten Years of National Data
Earla JR1, Paranjpe R1, Kachru N2, Aparasu RR1, 1University of Houston, Houston, TX, USA, 2Gilead Sciences Inc., Foster City,
CA, USA
3:15PM-3:30PM ND2 How Prescription Drug Cost for Disease Modifying Therapy (DMT) Impacts Overall Healthcare Spending Among
Individuals with Multiple Sclerosis
Kim Y1, Krause TM1, Freeman L2, 1The University of Texas Health Science Center at Houston School of Public Health,
Houston, TX, USA, 2The University of Texas Health Science Center at Houston McGovern Medical School, Houston, TX, USA
3:30PM-3:45PM ND3 Productivity Losses Among Patients with Migraine: An Analysis of Erenumab Clinical Trial Data
Porter JK1, Di Tanna GL1, Lipton RB2, Sapra S3, Villa G1, 1Amgen (Europe) GmbH, Zug, Switzerland, 2Albert Einstein College of
Medicine, Bronx, NY, USA, 3Amgen Inc, Thousand Oaks, CA, USA
3:45PM-4:00PM ND4 Cost-Utility Analysis Comparing Abobotulinumtoxina with Onabotulinumtoxina for the Treatment of Pediatric
Lower Limb Spasticity
Johnston KM1, Hansen RN2, Cheung A1, Liovas A3, Armstrong A3, Danchenko N4, Bains S5, Dinet J4, Sullivan SD2, 1Broadstreet
Health Economics & Outcomes Research, Vancouver, BC, Canada, 2University of Washington, Seattle, WA, USA, 3Ipsen
Biopharmaceuticals Canada, Mississauga, ON, Canada, 4Ipsen Global, Boulogne-Billancourt, France, 5Ipsen US, Basking
Ridge, NJ, USA
36 #ISPORBaltimore
Invitational Group Meetings

The following is a list of the by invitation only ISPOR group meetings during ISPOR 2018. ISPOR members worldwide are actively participating in
ISPOR working groups to advance global health outcomes research and the use of this research in healthcare decisions. These ISPOR groups
provide an opportunity for members to contribute to translating outcomes research into healthcare decisions.
Please note: invitees will receive an email reminder and notification of any changes to this ISPOR group meeting schedule
SUNDAY, MAY 20 Lunch on your own for short course delegates

8:30AM-4:30PM Pharmacy
ISPOR HTA - P&T & Therapeutics Roundtable
Roundtable Ballroom III (Level 400)
12:00PM-1:15PM ISPOR Joint Councils Lunch Ballroom II (Level 400)
12:30PM-4:00PM ISPOR Student Leadership Retreat Ballroom I (Level 400)
1:30PM-4:00PM ISPOR Institutional Council Roundtable Ballroom II (Level 400)
2:30PM-3:30PM ISPOR Publications Management Advisory Board (MAB) / ISPOR Journal Room 324-325 (Level 300)
Editors-in-Chief Joint Business Meeting
4:00PM-6:00PM ISPOR IC/FAC Competency Assessment Framework Ballroom II (Level 400)
4:30PM-5:30PM ISPOR Past-Presidents Council Room 324-325 (Level 300)
MONDAY, MAY 21 12:00PM-2:15PM Lunch for delegates served in the Exhibit Poster Hall
7:15AM-8:30AM
7:15AM-8:15AM ISPOR Medical Devices and Diagnostics Special Interest Group Room 323 (Level 300)
7:15AM-8:15AM ISPOR Statistical Methods in Health Economics and Outcomes Research SIG Room 324-325 (Level 300)
7:15AM-8:15AM ISPOR CEE Consortium Members Room 315 (Level 300)
7:30AM-8:15AM
7:15AM-8:15AM ISPOR Asia Consortium Business Meeting Room 314 (Level 300)
10:30AM-12:00PM ISPOR Optimization Task Force Room 323 (Level 300)
11:00AM-12:00PM ISPOR Latin America Consortium Industry Committee Working Group Room 320 (Level 300)
12:00PM-1:00PM ISPOR Midwest Regional Chapter Room 324-325 (Level 300)
12:00PM-4:45PM ISPOR Patient Representatives Roundtable Room 308 (Level 300)
12:15PM-1:45PM ISPOR Africa Network Members Room 315 (Level 300)
12:30PM-1:30PM ISPOR Oncology Special Interest Group Room 320 (Level 300)
3:00PM-4:00PM ISPOR Asia Consortium Health Technology Producers (Industry) Committee 315 (Level
Room 321-322 300)300)
(Level
3:30PM-4:30PM ISPOR Mexico Chapter Room 320 (Level 300)
4:00PM-5:00PM ISPOR Latin America Consortium Business Meeting Room 316-317 (Level 300)
5:00PM-6:30PM ISPOR Health Sciences Policy Council Room 324-325 (Level 300)
5:15PM-7:15PM ISPOR Chapter Leader Workshop Room 314 (Level 300)
7:30PM-9:00PM ISPOR ViH Editorial Board and Editorial Advisory Board Room 315 (Level 300)
TUESDAY, MAY 22 12:00PM-2:15PM Lunch for delegates served in the Exhibit Poster Hall
7:00PM-8:00PM
7:00AM-8:00AM ISPOR Global Engagement Council Room 324-325 (Level 300)
7:15AM-8:15AM ISPOR Value & Outcomes Spotlight Editorial Advisory Board Room 320 (Level 300)
7:15AM-8:15AM ISPOR Health State Utility Estimates in Cost-Effectiveness Models Task Force Room 323 (Level 300)
7:15AM-8:15AM ISPOR Patient Centered Special Interest Group Room 315 (Level 300)
11:00AM-12:00PM ISPOR Latin America Consortium Product Planning Committee Room 324-325 (Level 300)
11:00AM-12:00PM ISPOR Asia Pacific 2018 Conference Committee Room 315 (Level 300)
12:00PM-2:00PM ISPOR Student & Faculty Advisor Luncheon Room 314 (Level 300)
12:15PM-1:45PM ISPOR Arabic Network Members Room 320 (Level 300)
12:30PM-1:30PM ISPOR Digest of International Databases Special Interest Group Room 323 (Level 300)
3:15PM-4:45PM ISPOR Value of Information Task Force Room 323 (Level 300)
3:30PM-5:00PM ISPOR Student Roundtable Event Room 314 (Level 300)
3:45PM-4:45PM Value in Health Regional Issues Editorial Board & Editorial Advisory Board Room 315 (Level 300)
3:45PM-4:45PM ISPOR Ukraine Chapter Room 320 (Level 300)
WEDNESDAY, MAY 23 11:45AM-1:45PM Lunch for delegates served in the Exhibit Poster Hall
9:00AM-10:00AM ISPOR Stated Preference Methods Special Interest Group Room 320 (Level 300)
11:45AM-1:15PM ISPOR Performance Outcomes Emerging Good Practices Task Force Room 320 (Level 300)
www.ispor.org 37
< advertisement >
38 #ISPORBaltimore
ISPOR2018
May 19-23, 2018
Baltimore, MD, USA
Poster - Exhibit Program

Research Poster Presentations Overview
Exhibit Program Overview
Exhibitor Listing
Exhibit/Poster Hall Floor Plan
www.ispor.org 39
Research Poster Presentations Overview

Over 1,600 poster presentations will be on display during the conference in the Poster and Exhibit Hall (Halls B-D).
• Presenters are required to be with their posters during the Poster Author Discussion Hour.
• The poster hall is organized in rows (A-K) and each poster board is numbered accordingly (eg C29). Row locations (by topic) are
available in the table below.
• Each poster presentation has been assigned a specific numbered board location. Please note this is different than the poster code
(eg PHP1, PCV57), which was assigned to each poster presentation upon acceptance.
• Poster presentation titles and authors, as well as the numbered board location, are available on the myISPORBaltimore.zerista.com
conference platform and mobile app. This information is also available as a PDF on the ISPOR website.
• An author index will be available in Value in Health 21 (Suppl. 1). The issue will be ONLINE ONLY, available one month after the
meeting.
• NEW! Poster presentations from Research Poster Award finalists are available for viewing at the ePoster Viewing Area for the
duration of the conference.
POSTER PRESENTATION SESSIONS POSTER PRESENTER POSTER AUTHOR PRESENTER

LOCATION SET UP TIME DISPLAY DISCUSSION DISMANTLE
HOURS HOUR TIME*
SESSION I: MONDAY, MAY 21

PRM: RESEARCH ON METHODS Rows A1-C29 8:15AM - 8:30AM 8:30AM - 2:00PM 1:00PM - 2:00PM 2:00PM
PCV: CARDIOVASCULAR DISORDERS Rows C30-G2
PMS: MUSCULAR-SKELETAL DISORDERS Rows G3-I19
PND: NEUROLOGICAL DISORDERS Rows I20-K23
SESSION II: MONDAY, MAY 21

PHS: HEALTH SERVICES Rows A1-D6 3:15PM - 3:30PM 3:30PM - 7:30PM 6:30PM - 7:30PM 7:30PM
PDB: DIABETES/ENDOCRINE DISORDERS Rows D7-H1
PRS: RESPIRATORY-RELATED DISORDERS Rows H2-J7
PCP: CONCEPTUAL PAPERS Rows J8-K14
SESSION III: TUESDAY, MAY 22

PHP: HEALTHCARE USE & POLICY STUDIES Rows A1-F24 8:15AM - 8:30AM 8:30AM - 2:00PM 1:00PM - 2:00PM 2:00PM
PIH: INDIVIDUAL’S HEALTH Rows G1-H21
PMH: MENTAL HEALTH Rows H22-K18
SESSION IV: TUESDAY, MAY 22

PCN: CANCER Rows A1-H2 3:15PM - 3:30PM 3:30PM - 7:30PM 6:30PM - 7:30PM 7:30PM
PGI: GASTROINTESTINAL DISORDERS Rows H3-I13
PSS: SENSORY SYSTEMS DISORDERS Rows I14-J20
PUK: URINARY/KIDNEY DISORDERS Rows J21-K18
SESSION V: WEDNESDAY, MAY 23

PMD: MEDICAL DEVICES/DIAGNOSTICS Rows A1-C21 8:15AM - 8:30AM 8:30AM - 1:30PM 12:30PM - 1:30PM 1:30PM
PIN: INFECTION Rows C22-F9
PSY: SYSTEMIC DISORDERS/CONDITIONS Rows F10-K17
*Posters that are not removed at the scheduled dismantle times will be discarded.
40 #ISPORBaltimore
Exhibit Program Overview

Exhibits Viewing Hours Halls B-D (Level 100)
Monday, May 21 8:30AM - 7:45PM
Tuesday, May 22 8:30AM - 7:45PM
Wednesday, May 23 8:30AM - 2:00PM
Networking and Lounges

Business Café Sponsored by Complete HEOR Solutions (CHEORS): Booth #601, Exhibit Hall
Charging Lounge Provided by Syneos Health: Booth #239, Exhibit Hall
Public Networking Lounges Sponsored by IQVIA and analytica|LASER: Level 300 Terrace
Internet Access/Wi-Fi Sponsored by IQVIA: ISPOR/Password: IQVIA2018
Network Seating Level 400 Foyer
Schedule
Sunday, May 20
8:00AM - 11:59PM Exhibitor Set-Up (No re-entry after 10:00PM)
12:00PM - 6:00PM Digital Health Showcase
Monday, May 21
7:00AM - 8:30AM Exhibitor Set-Up
8:30AM - 7:45PM Exhibits Viewing
10:30AM - 11:00AM Coffee Break & Exhibits Viewing Sponsored by Pharmerit International
10:30AM - 6:00PM Digital Health Showcase
12:00PM - 2:15PM Lunch, Exhibits & Research Poster Presentations Viewing
3:15PM - 3:45PM Coffee Break & Exhibits Viewing
6:00PM - 7:45PM Exhibitors’ Open House Reception Sponsored by Complete HEOR Solutions (CHEORS)
Tuesday, May 22
10:30AM - 11:00AM Coffee Break & Exhibits Viewing
12:00PM - 2:15PM Lunch, Exhibits & Research Poster Presentations Viewing
3:15PM - 3:45PM Coffee Break & Exhibits Viewing
6:00PM - 7:45PM Exhibitors’ Wine & Cheese Reception Provided by ISPOR
Wednesday, May 23
9:30AM - 10:00AM Coffee Break & Exhibits Viewing
11:45AM - 1:45PM Lunch, Exhibits Viewing
2:00PM - 10:00PM Exhibitor Dismantle
www.ispor.org 41
Exhibitor Listing
Company name Exhibit Location Company name Exhibit Location Company name Exhibit Location
Adelphi 323 ( 3 booths) FACIT.org/FACITtrans 339 OM1 329 (2 booths)
Amaris 127 Future Science Group 718 Optum* 401 (4 booths)
American Journal of Managed Care 103 Genesis Research 225 (2 booths) PAREXEL 435 (2 booths)
AMPLEXOR 135 GfK 436 (2 booths) Pharmerit International* 311 (3 booths)
Analysis Group, Health Analytics LLC 439 Policy Analysis Inc. (PAI) 326
a Certara Company 101 (2 booths) HealthCore, Inc.* 305 (4 booths) Pope Woodhead &
Analytica Laser* 425 (4 booths) Associates Ltd 113 (2 booths)
HOPE Rutgers University Table #7
AplusA Real World 125 PRA Health Sciences 235
IBM Watson Health* 219 (4 booths)
Barrington James 229 (2 booths) Precision for Value (Part of
ICON / Mapi Research Trust
Precision Value & Health)* 701 (4 booths)
BaseCase, Inc. USA 500 (2 booths) 607 (4 booths)
Premier, Inc. 111
BHE 226 IMPAQ International 227
Prioritis Ltd 348
Boston Strategic Partners, Inc. Intexo Srl 445 (2 booths)
811 (2 booths) PRMA Consulting 807 (2 booths)
Ipsos Healthcare 441 (2 booths)
BresMed 908 Rare Patient Voice 512
IQVIA* 201 (8 booths)
Bristol Myers Squibb 350 RealHealthData 222 (2 booths)
ISPOR 213 (4 booths)
Cardinal Health 504 (2 booths) R-Squared Talent Solutions
Jefferson College of Population
133 (2 booths)
Clinical Practice Research Health 716
RTI Health Solutions* 707 (4 booths)
Datalink (CPRD) 105 Johns Hopkins Bloomberg
School of Public Health Table #9 Sciformix Corporation 809
Complete HEOR
Solutions (CHEORS) 1000 (5 booths) Kantar Health 202 (4 booths) SHYFT Analytics 245 (2 booths)
Cornerstone Research KEVA Health Digital Health Showcase SIRIUS Market Access 414
Group Inc. 410 (2 booths)
Klein Hersh International Table #2 STATinMED Research 333 (2 booths)
Covance Market Access 317 (2 booths) Lifescience Dynamics 137 Syneos Health* 407 (4 booths)
CRA, Charles River Associates 249 MA Provider 119 Taylor & Francis 510
Creativ-Ceutical 617 MAPES Table #12 Translational Technologies
Crystallise Ltd 346 International, LLC Table #4
Market Access Solutions 121
CTI Clinical Trial and TransPerfect 218 (2 booths)
Market Access
Consulting Services 321 (2 booths) Transformation 615 (2 booths) TreeAge Software 514
CVS Health 117 (2 booths) MarksMan Healthcare Solutions Table #5 TriNetX 713 (4 booths)
Decision Resources Group 259 (2 booths) McKesson Specialty Health 123 Tufts Medical Center 508
Digital Health Outcomes Medical Data Vision Co. Ltd. 247 University of Maryland –
& GMAS 129 (2 booths) Pharmaceutical Health Services
Merck 253
Duke Clinical Research Research Graduate Program Table #3
Monument Analytics 516
Institute 432 (2 booths) Vitaccess 137
MS in Regulatory Science Program,
Dymaxium 422 (2 booths) WIRB-Copernicus Group 210
University of Maryland Table #14
eMAX Health Systems 107 Worldwide Clinical Trials 238
National Pharmaceutical Council 426
Envision Pharma Ltd 234 (2 booths) Xavier University Table #10
Navigant 334
Evid Science Digital Health Showcase Xcenda 801 (4 booths)
Normin Health Table #8
Evidence Partners Inc. 233 (2 booths) ZRx Outcomes Research Inc. Table #1
Novartis Pharmaceuticals
Evidera* 419 ( 4 booths) Corporation Table #6 ZS 141 (2 booths)
Exponent 109 Novosys Health 337 * Sponsoring organizations
42 #ISPORBaltimore
Exhibit/Poster Hall Floor Plan
Poster Presentations:
Session I: Monday, May 21 8:30AM-2:00PM
Level 100
Session II: Monday, May 21 3:30PM-7:30PM
Session III: Tuesday, May 22 8:30AM-2:00PM
Session IV: Tuesday, May 22 3:30PM-7:30PM
Session V: Wednesday, May 23 8:30AM-1:30PM
Exhibits will be on view in Halls B-D during the

following hours:
Monday, May 21 8:30AM–7:45PM
Tuesday, May 22 8:30AM–7:45PM
Wednesday, May 23 8:30AM–2:00PM
DE FG HI J K
Poster C
Help
Desk B
www.ispor.org 43
< advertisement >
44 #ISPORBaltimore
ISPOR2018
May 19-23, 2018
Baltimore, MD, USA
ISPOR Scientific and Service Awards Program

The ISPOR Awards Program is designed to foster and recognize excellence and outstanding technical
achievement in pharmacoeconomics / health economics and outcomes research. In addition to scientific
achievement, ISPOR also bestows lifetime achievement and leadership awards to those who advance these
disciplines in the field and for their service to the Society.
AWARD PRESENTATION DATES AND TIMES

Award presentations will take place in Hall A (Level 100)
We encourage all to attend to show their support to the award recipients for their achievements.
Monday, May 21, 2018: 8:30AM

• ISPOR Avedis Donabedian Award
Tuesday, May 22, 2018: 8:30AM

• ISPOR Marilyn Dix Smith Leadership Award
• ISPOR Value in Health Paper of the Year Award
• ISPOR Value in Health Regional Issues Excellent Article Award
• ISPOR Award for Excellence in Methodology in Pharmacoeconomics and Health Outcomes Research
• ISPOR Award for Excellence in Application of Pharmacoeconomics and Health Outcomes Research
• ISPOR Bernie J. O’Brien New Investigator Award
Wednesday, May 23, 2018: 10:00AM

• ISPOR Service Awards
• ISPOR Student Awards
• PhRMA Foundation Awards
www.ispor.org 45
ISPOR LIFETIME ACHIEVEMENT AND LEADERSHIP AWARDS

2018 ISPOR AVEDIS DONABEDIAN OUTCOMES RESEARCH LIFETIME ACHIEVEMENT AWARD
ISPOR’s most prestigious award, the Avedis Donabedian Outcomes Research Lifetime Achievement Award was established
to honor the body of work and contributions to the field made by the late Avedis Donabedian, MD, MPH. The Award
recognizes an individual’s outstanding, life-long achievement in improving health outcomes.
2018 ISPOR AVEDIS DONABEDIAN OUTCOMES RESEARCH LIFETIME ACHIEVEMENT AWARDEE
F. Reed Johnson, PhD, Professor, Duke School of Medicine, Duke Clinical Research Institute, Duke University, Durham, NC,
USA
F. Reed Johnson, PhD, has more than 40 years of academic and research experience in health and environmental
economics. He has served on the faculties of universities in the United States, Canada, and Sweden, as Distinguished Fellow
at Research Triangle Institute, and currently as Professor in the Departments of Population Health Sciences and Medicine,
Duke School of Medicine, as well as appointments in the Center for Health Measurement and the Duke Clinical Research
Institute. As a staff member in the US Environmental Protection Agency’s environmental economics research program
during the 1980s, Dr. Johnson helped pioneer development of nonmarket valuation techniques. These methods are now
widely used in federally mandated regulatory impact studies, for estimating the value of improved health outcomes, and
for quantifying patients’ tolerance for treatment-related risks. Dr. Johnson has over 140 publications in books and peer-
reviewed medical, health-economics, environmental-economics, and general economics journals. He coauthored a book on
techniques for using existing environmental and health value estimates for policy analysis. He led the first FDA-sponsored
study to quantify patients’ willingness to accept benefit-risk tradeoffs for new health technologies. The study was used to
inform recent FDA guidance on submitting patient-preference data to support regulatory reviews of medical devices. His
current research involves quantifying patients’ willingness to accept side-effect risks in return for therapeutic benefits and
estimating general time equivalences among health states. He is a founding member of the International Academy of Health
Preference Research. Dr. Johnson currently serves on the editorial board for The Patient, the Science Advisory Board for the
U.S. Environmental Protection Agency, and the ISPOR Health Science Policy Council.
2018 ISPOR MARILYN DIX SMITH LEADERSHIP AWARD

The Marilyn Dix Smith Leadership Award was established in 2014 in honor of ISPOR’s Founding Executive Director, Marilyn
Dix Smith, RPh, PhD. The Award recognizes one individual each year who has provided extraordinary leadership to the
Society.
2018 ISPOR MARILYN DIX SMITH LEADERSHIP AWARDEE
Finn Børlum Kristensen, PhD, MD, Professor, Faculty of Health Sciences, University of Southern Denmark, Odense,
Denmark
Finn Børlum Kristensen, PhD, MD, has been a professor in Health Services Research and HTA at Faculty of Health Sciences,
University of Southern Denmark since 1999. Dr. Kristensen headed the Coordinating Secretariat of the European Network
for HTA, EUnetHTA (www.eunethta.eu) from its inception in 2006 and was Chairman of the EUnetHTA Executive Committee
until 2016. He was head of Danish Centre for HTA (DACEHTA) at the Danish Health Authority from its establishment (1997-
2009). His PhD is in epidemiology and he is a medical specialist in public health. He also worked as a primary care physician
for several years. He publishes frequently in scientific journals and was editor of a Health Technology Assessment Handbook. Dr.
Kristensen was Chairman of the International Network of Agencies for Health Technology Assessment (INAHTA) from 2003 to
2006 and served on the ISPOR Board of Directors from 2011 to 2013 and has chaired the ISPOR HTA Council since 2013.
ISPOR VALUE IN HEALTH AWARD

ISPOR AWARD FOR VALUE IN HEALTH PAPER OF THE YEAR
The ISPOR Award for Value in Health Paper of the Year was established in 2011 to promote quality research, originality, and
utility in healthcare decisions for articles published in Value in Health. The award is given to the best paper published (in
print) in the previous calendar year.
2018 ISPOR VALUE IN HEALTH PAPER OF THE YEAR AWARDEE
Richard Cookson, PhD, Centre for Health Economics, University of York, York, UK
For the paper, “Using Cost-Effectiveness Analysis to Address Health Equity Concerns,” Value in Health 2017;20(2):206-212.
Authors: Richard Cookson, Andrew J. Mirelman, Susan Griffin, Miqdad Asaria, Bryony Dawkins, Ole Frithjof Norheim, Stéphane
Verguet, Anthony J. Culyer
Richard Cookson, PhD, is a professor and NIHR Senior Research Fellow at the Centre for Health Economics, University of
York. Dr. Cookson has helped to pioneer “equity-informative” methods of evaluation and monitoring that quantify who gains
and loses from health policy decisions. He has helped to develop methods of distributional cost-effectiveness analysis,
methods of health equity monitoring for healthcare quality assurance, and methods for investigating public concern for
reducing health inequality. He co-chaired the economics sub-group for the WHO review of health inequality in Europe
from 2010 to 2012, served on NICE advisory committees from 2002 to 2009, and was seconded to the UK Prime Minister’s
Delivery Unit in 2010. He is currently an honorary public health academic for Public Health England and member of the NHS
Advisory Committee for Resource Allocation.
46 #ISPORBaltimore
ABSTRACT
This article serves as a guide to using cost-effectiveness analysis (CEA) to address health equity concerns. We first introduce the
“equity impact plane,” a tool for considering trade-offs between improving total health—the objective underpinning conventional
CEA—and equity objectives, such as reducing social inequality in health or prioritizing the severely ill. Improving total health may
clash with reducing social inequality in health, for example, when effective delivery of services to disadvantaged communities
requires additional costs. Who gains and who loses from a cost-increasing health program depends on differences among people in
terms of health risks, uptake, quality, adherence, capacity to benefit, and— crucially—who bears the opportunity costs of diverting
scarce resources from other uses. We describe two main ways of using CEA to address health equity concerns: 1) equity impact
analysis, which quantifies the distribution of costs and effects by equity relevant variables, such as socioeconomic status, location,
ethnicity, sex, and severity of illness; and 2) equity trade-off analysis, which quantifies trade-offs between improving total health
and other equity objectives. One way to analyze equity trade-offs is to count the cost of fairer but less cost-effective options in terms
of health forgone. Another method is to explore how much concern for equity is required to choose fairer but less cost-effective
options using equity weights or parameters. We hope this article will help the health technology assessment community navigate
the practical options now available for conducting equity-informative CEA that gives policymakers a better understanding of equity
impacts and trade-offs.
(Co-author Dr. Andrew Mirelman, MPH, PhD, from the University of York will accept the award on behalf of Dr. Cookson.)
ISPOR RESEARCH EXCELLENCE AWARDS

ISPOR AWARD FOR EXCELLENCE IN METHODOLOGY IN HEALTH ECONOMICS AND OUTCOMES
RESEARCH
The ISPOR Award for Excellence in Methodology in Health Economics and Outcomes Research recognizes an outstanding
paper in the field of health economics and outcomes research methodology. The award is based upon publications that
have appeared in respected peer-reviewed journals and other communication venues between January 1, 2017 and
December 31, 2017.
2018 ISPOR AWARD FOR EXCELLENCE IN METHODOLOGY IN HEALTH ECONOMICS AND OUTCOMES RESEARCH
AWARDEE
Laura A. Hatfield, PhD, Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
For the paper, “Regulator Loss Functions and Hierarchical Modeling for Safety Decision Making” Med Decis Making 2017;37:
512–522.
Authors: Laura A. Hatfield, Christine M. Baugh, Vanessa Azzone, Sharon-Lise T. Normand
Laura Hatfield, PhD, is an associate professor of healthcare policy (biostatistics). Her research focuses on trade-offs and
relationships among health outcomes. She develops statistical methods that incorporate multiple sources of information,
relationships among outcomes, and loss functions to improve decision making. Dr. Hatfield has expertise in Bayesian
hierarchical and multiple outcome modeling. In applied research, Dr. Hatfield has evaluated interventions ranging from
price transparency initiatives to home care, and from accountable care organizations to patient-centered medical homes.
She has modeled temporal and geographic variation in medical device use and outcomes. Inspired by this applied work,
Dr. Hatfield is currently working to improve methods for causal inference using difference-in-differences designs. With
Dr. Sherri Rose, she co-leads the Health Policy Data Science Lab. Dr. Hatfield received her BS in genetics from Iowa State
University and her MS and PhD in biostatistics from the University of Minnesota.
ABSTRACT
Background. Regulators must act to protect the public when evidence indicates safety problems with medical devices. This requires
complex tradeoffs among risks and benefits, which conventional safety surveillance methods do not incorporate. Objective. To
combine explicit regulator loss functions with statistical evidence on medical device safety signals to improve decision making.
Methods. In the Hospital Cost and Utilization Project National Inpatient Sample, we select pediatric inpatient admissions and
identify adverse medical device events (AMDEs). We fit hierarchical Bayesian models to the annual hospital-level AMDE rates,
accounting for patient and hospital characteristics. These models produce expected AMDE rates (a safety target), against which
we compare the observed rates in a test year to compute a safety signal. We specify a set of loss functions that quantify the costs
and benefits of each action as a function of the safety signal. We integrate the loss functions over the posterior distribution of
the safety signal to obtain the posterior (Bayes) risk; the preferred action has the smallest Bayes risk. Using simulation and an
analysis of AMDE data, we compare our minimum-risk decisions to a conventional Z score approach for classifying safety signals.
Results. The 2 rules produced different actions for nearly half of hospitals (45%). In the simulation, decisions that minimize Bayes
risk outperform Z score–based decisions, even when the loss functions or hierarchical models are misspecified. Limitations. Our
method is sensitive to the choice of loss functions; eliciting quantitative inputs to the loss functions from regulators is challenging.
Conclusions. A decision-theoretic approach to acting on safety signals is potentially promising but requires careful specification of
loss functions in consultation with subject matter experts.
www.ispor.org 47
ISPOR AWARD FOR EXCELLENCE IN APPLICATION OF HEALTH ECONOMICS AND OUTCOMES RESEARCH
The ISPOR Award for Excellence in Application of Health Economics and Outcomes Research recognizes an outstanding
paper in the field of health economics and outcomes research practical application. The award is based upon publications
that have appeared in respected peer-reviewed journals and other communication venues between January 1, 2017 and
December 31, 2017.
2018 ISPOR AWARD FOR EXCELLENCE IN APPLICATION OF HEALTH ECONOMICS AND OUTCOMES RESEARCH
AWARDEE
Rebecca Myerson, MHP, PhD, Assistant Professor of Pharmaceutical and Health Economics, School of Pharmacy and USC
Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA, USA
For the paper, “Hospital Admissions for Myocardial Infarction and Stroke Before and After the Trans-Fatty Acid Restrictions in New
York,” JAMA Cardiol 2017;2:627-634.
Authors: Rebecca Myerson, Eric J. Brandt, Marcelo Coca Perraillon, Tamar S. Polonsky
Rebecca Myerson, MPH, PhD, is an assistant professor at the University of Southern California and affiliate of USC’s
Schaeffer Center for Health Policy and Economics. Dr. Myerson holds a PhD in public policy with a concentration in applied
econometrics from University of Chicago and an MPH from University of Washington. With the goal of informing policy
to improve health, her research aims to quantify the impacts of policies on incidence and treatment of diabetes and
cardiovascular disease. Her health economics research assesses whether informing patients about their health biomarkers
and health insurance options closes gaps in uptake of needed care. Specific projects have analyzed trans fat restrictions,
screening interventions, assistance programs for health insurance enrollment, and Medicaid eligibility expansions. She has
received research funding from the Agency for Healthcare Research and Quality and a Fulbright Scholarship. She gratefully
accepts this award on behalf of her coauthors, Eric Brandt, Marcelo Coca-Peraillon, and Tamar Polonsky.
ABSTRACT
OBJECTIVE: To determine whether TFA restrictions in NYS counties were associated with fewer hospital admissions for myocardial
infarction (MI) and stroke compared with NYS counties without restrictions. DESIGN, SETTING, AND PARTICIPANTS: We conducted a
retrospective observational pre-post study of residents in counties with TFA restrictions vs counties without restrictions from 2002 to
2013 using NYS Department of Health’s Statewide Planning and Research Cooperative System and census population estimates. In
this natural experiment, we included those residents who were hospitalized for MI or stroke. The data analysis was conducted from
December 2014 through July 2016. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of MI and stroke
events based on primary discharge diagnostic codes from hospital admissions in NYS. Admission rates were calculated by year, age,
sex, and county of residence. A difference-in-differences regression design was used to compare admission rates in populations with
and without TFA restrictions. Restrictions were only implemented in highly urban counties, based on US Department of Agriculture
Economic Research Service Urban Influence Codes. Nonrestriction counties of similar urbanicity were chosen to make a comparison
population. Temporal trends and county characteristics were accounted for using fixed effects by county and year, as well as linear
time trends by county. We adjusted for age, sex, and commuting between restriction and nonrestriction counties. RESULTS: In 2006,
the year before the first restrictions were implemented, there were 8.4 million adults (53.6%female) in highly urban counties with TFA
restrictions and 3.3 million adults (52.3%female) in highly urban counties without restrictions. Twenty-five counties were included
in the nonrestriction population and 11 in the restriction population. Three or more years after restriction implementation, the
population with TFA restrictions experienced significant additional decline beyond temporal trends in MI and stroke events combined
(−6.2%; 95%CI, −9.2% to −3.2%; P < .001) and MI (−7.8%; 95%CI, −12.7% to −2.8%; P = .002) and a nonsignificant decline in stroke
(−3.6%; 95%CI, −7.6%to 0.4%; P = .08) compared with the nonrestriction populations. CONCLUSIONS AND RELEVANCE The NYS
populations with TFA restrictions experienced fewer cardiovascular events, beyond temporal trends, compared with those without
restrictions.
ISPOR BERNIE J. O’BRIEN NEW INVESTIGATOR AWARD

The ISPOR Bernie J. O’Brien New Investigator Award was established in 2004 to honor the long-standing commitment of
Bernie J. O’Brien, PhD to training and mentoring new scientists in the fields of outcomes research and pharmacoeconomics.
The recipient must be an ISPOR member with evidence of exceptional promise as assessed by evaluating the nominee’s
emerging body of technical and scholarly work in the fields of pharmacoeconomics and outcomes research.
2018 ISPOR BERNIE J. O’BRIEN NEW INVESTIGATOR AWARDEE
Sherri Rose, PhD, Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
Sherri Rose, PhD, is an associate professor in the Department of Health Care Policy at Harvard Medical School, where her
work is centered on developing and integrating innovative statistical approaches to advance human health. Broadly, Dr.
Rose’s methodological research focus is nonparametric machine learning for causal inference and prediction. Within health
policy, Dr. Rose works on risk adjustment, comparative effectiveness research, and health program impact evaluation. She
also co-leads the Health Policy Data Science Lab at Harvard where she directs projects in computational health economics
and clinical informatics. Dr. Rose coauthored the first book on machine learning for causal inference, and her recent honors
include an NIH Director’s New Innovator Award to develop robust estimators for generalizability. Her research has been
featured in The New York Times, USA Today, Slate, and The Boston Globe. Dr. Rose received her PhD in biostatistics from UC
Berkeley before completing an NSF Mathematical Sciences Postdoctoral Research Fellowship at Johns Hopkins University.
48 #ISPORBaltimore
ISPOR SERVICE AWARDS

The ISPOR Service Awards recognize members who have served on the ISPOR Board of Directors or have significantly
contributed to the vision and mission of the Society
ISPOR 2016–2018 BOARD OF DIRECTORS SERVICE AWARDS

• PRESIDENT (2016-2017) & PAST PRESIDENT (2017-2018) Lou Garrison, PhD, Professor, Pharmaceutical Outcomes
Research & Policy Program School of Pharmacy University of Washington Seattle, WA, USA
• DIRECTOR (2016-2018) Gordon G. Liu, PhD, PKU Yangtze River Scholar Professor of Economics, Peking University
National School of Development and Director, PKU China Center for Health Economic Research Beijing, China
• DIRECTOR (2016-2018) Joanna Lis, MSc, MBA, PhD, Director of Market Access, Sanofi-Aventis, Warsaw, Poland
• DIRECTOR (2016-2018) Rosanna Tarricone, MSc, PhD, Associate Professor, Bocconi University, Milan, Italy
• DIRECTOR (2016-2018) John Watkins, MPH, PharmD, Formulary Manager, Premera Blue Cross Mountlake Terrace,
WA, USA
ISPOR DISTINGUISHED SERVICE AWARDS

VALUE IN HEALTH CO-EDITOR (2010-2018)
• Ya-Chen (Tina) Shih, PhD, MS, University of Texas MD Anderson Cancer Center, Houston, TX, USA
• Richard Willke, PhD, CSO, ISPOR, Lawrenceville, NJ, USA
VALUE IN HEALTH REGIONAL ISSUES CO-EDITOR-IN-CHIEF — ASIA & LA (2012-2017)

• Bong-Min Yang, PhD, Seoul National University, Seoul, Korea
• Federico Augustovski, MD, MSc, PhD, Director, Health Technology Assessment and Health Economics Department
of the Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Buenos Aires, Argentina
VALUE IN HEALTH REGIONAL ISSUES CO-EDITOR — LA (2015-2017)

• Victor Zarate, MD, MSc, PhD, Chilean Ministry of Health, Santiago, Chile
ISPOR CODE OF ETHICS TASK FORCE CO-CHAIRS (2015-2017)

• Francis Palumbo, PhD, Executive Director and Professor, University of Maryland, Center on Drugs and Public Policy,
Baltimore, MD, USA
• Jessica Santos, PhD, Global Compliance and Quality Director, Kantar Health, Cambridge, UK
ISPOR VALUE OF INFORMATION ANALYSIS FOR RESEARCH DECISIONS EMERGING GOOD PRACTICES TASK FORCE
CO-CHAIRS (2016-2018)
• Claire Rothery, PhD, Senior Research Fellow in Health Economics, Centre for Health Economics, University of York,
York UK
• Elisabeth Fenwick, PhD, Senior Principal, ICON, Abingdon, UK
ISPOR INSTITUTIONAL COUNCIL CHAIR (2018)

• Mark Cziraky, PharmD, Vice President, Research, HealthCore, Inc., Wilmington, DE, USA
ISPOR STUDENT AWARDS

The ISPOR Student Chapter President Service Awards (Distinguished Service Award) recognize selected ISPOR chapter
presidents who have provided exemplary service to their university and who have demonstrated their leadership through
involvement with the ISPOR Student Network
ISPOR STUDENT NETWORK CHAIR (2017-2018)

• Blythe Adamson, MPH, University of Washington, Seattle, WA, USA
ISPOR STUDENT CHAPTER PRESIDENTS

The following students served as 2017-2018 President of the ISPOR Student Chapter at the university indicated below:
ISPOR STUDENT CHAPTER PRESIDENTS
• Rhys Axon, University of Arizona
• Laura Clark, UNC, Charlotte
• Koen Degeling, University of Twente
• Mihaela Vladimirova Georgieva, UNC, Chapel Hill
• Junjie Ma, University of Utah
• Ruchira Mahashabde, University of Toledo
• Charles Aruchi Opurum, University of Nigeria, Nsukka
www.ispor.org 49
• Xavier Pouwels, Maastricht

• Drishti Shah, West Virginia University
• Zoe Szewczyk, University of Newcastle
OUTSTANDING ISPOR STUDENT CHAPTER OF THE YEAR AWARD

The Outstanding ISPOR Student Chapter of the Year Award was established in 2007 to recognize ISPOR Student Chapters
that provide exemplary service to its university.
AWARD RECIPIENTS:
First Prize: West Virginia University
Second Prize: Mercer University
Third Prize: University of Arizona
BEST NEW ISPOR STUDENT CHAPTER AWARD

The Best New ISPOR Student Chapter of the Year Award was established in 2011 to recognize the hard work and efforts of
ISPOR’s newest chapters to join the Student Network during the year.
Best New Chapter: Enschede, Netherlands, University of Twente
PhRMA FOUNDATION 2018 AWARDS IN HEALTH OUTCOMES

The PhRMA Foundation awards support young scientists in disciplines important to the pharmaceutical industry by awarding
them competitive research fellowships and grants at a critical decision point at the outset of their careers. ISPOR is proud to
present these awards from the PhRMA Foundation at our meeting.
2018 PREDOCTORAL FELLOWSHIP IN HEALTH OUTCOMES

2018 AWARDEES
• N athaniel
Kathy D. Hendrix,
Trang, PharmD,Department
Emory University, University of
ofWashington, Comparative Health Outcomes, Policy, and Economics
Anthropology
(CHOICE) Institute
• Nathaniel D. Hendrix, PharmD, University of Washington, Comparative Health Outcomes, Policy, and Economics
• Ruixuan
(CHOICE) Jiang, PharmD, Univeristy of Illinois at Chicago, Department of Pharmacy Systems, Outcomes, and Policy
Institute
• Tessa J. Hastings, Auburn University, Department of Health Outcomes and Policy Research
2018
• UrielPOSTDOCTORAL FELLOWSHIP
Kim, Case Western Reserve INSchool
University HEALTH OUTCOMES
of Medicine, Department of Clinical Translational Science
2018 AWARDEE
• Ruixuan Jiang, PharmD, University of Illinois at Chicago, Department of Pharmacy Systems, Outcomes, and Policy
• Andrew David Wiese, MPH, PhD, Vanderbilt University Medical Center, Department of Health Policy
2018 POSTDOCTORAL FELLOWSHIP IN HEALTH OUTCOMES
2018 RESEARCH STARTER GRANTS IN HEALTH OUTCOMES
2018 AWARDEE
2018 AWARDEE
• Andrew David Wiese, MPH, PhD, Vanderbilt University Medical Center, Department of Health Policy
• Brittany R. Lapin, MPH, PhD, Cleveland Clinic, Department of Quantitative Health Sciences
2018 RESEARCH STARTER GRANTS IN HEALTH OUTCOMES
PhRMA FOUNDATION 2018 AWARDS IN VALUE ASSESSMENT
2018 AWARDEE
• Brittany R. Lapin, MPH, PhD, Cleveland Clinic, Department of Quantitative Health Sciences
2018 RESEARCH AWARDS IN VALUE ASSESSMENT
2018 AWARDEES
• Josh J. Carlson, PhD, University of Washington, Department of Pharmacy
• Shelby D. Reed, PhD, Duke University Clinical Research Institute, Population Health Science Department
• Gillian Sanders Schmidler, PhD, Duke University, Population Health Science Department
2018 CENTER OF EXCELLENCE AWARDS IN VALUE ASSESSMENT

2018 AWARDEES
• Susan dosReis, PhD, University of Maryland School of Medicine, Department of Pharmaceutical Health Services Research
• George J. Miller, PhD, Altarum Institute, Center for Sustainable Health Spending
50 #ISPORBaltimore
< advertisement >
www.ispor.org 51
N OW A VAI LA BLE : https://www.ispor.org/top10trends.pdf?v2
52 #ISPORBaltimore
The ISPOR Career Center and Onsite Job Board
can help you generate buzz for your HEOR-related job openings.
Here’s how:
• Job positions posted in a highly visible networking area at ISPOR 2018
• Advanced search capabilities and robust reporting analytics
• Resources for employers, including compliance information, tutorials on

creating strong job postings, and more!
• Receive alerts when candidates meet your search criteria
• Targeted marketing through ISPOR’s eNewsletters, email campaigns, and

publications that reach the audiences you need to influence.
www.ispor.org 53
ISPOR Conference Evaluation
We’re listening.
Please complete a simple online evaluation after the conference to help us plan for future conferences.
It’s simple, answer a few multiple-choice questions by Friday, June 8, 2018 using the ISPOR mobile app
or on the ISPOR website at www.ispor.org.
Be a voice and help us plan for 2019.
ISPOR Session Evaluation

Have thoughts about a particular session? We’re interested.
• Evaluate presentations through the ISPOR Mobile App
• Provide real-time responses immediately following the presentation
• 2-question evaluation for each presentation that can be accessed through the description portion
of the presentation on the app.
54 #ISPORBaltimore
Key Information
All research podium presentations are considered for an award. The top 10% of research
poster presentations, based on abstract review score, are considered for a poster presentation
award. These are identified with a rosette and will be judged during the conference.
Award recipients will be notified by email and recognized on the ISPOR website at the
conclusion of the conference.
WI-FI, INTERNET AND MOBILE APP ACCESS
ISPOR SOCIAL EVENT
Internet stations are provided in the Exhibit-Poster Hall located in Halls B-D (Level 100).
For the convenience of conference attendees, Wi-Fi is available in the convention center. TUESDAY, May 22 from 9:00-11:00PM
Tin Roof Baltimore
Network: ISPOR / Password: IQVIA2018
Join us for an evening of networking, light bar bites, and live music at the ISPOR Social
Wi-Fi is only intended for checking email and using the conference mobile app, not for Event at Tin Roof Baltimore. Known as the “Live Music Joint, where Everybody is Somebody,”
downloading files. Connection speeds will vary depending on the volume of users. Tin Roof offers a fun, inviting, eclectic, laid-back atmosphere. It is conveniently located
Download the mobile app on your smartphone or tablet: in Baltimore’s popular Power Plant Live and only 1 block away from the world famous
Downtown Inner Harbor. So whether you are coming to dance or to grab a drink, this is the
ISPOR perfect opportunity to reconnect with your ISPOR peers! Separate registration required.
Separate registration required: $30 per person. Price includes light bar bites and
Can’t download the app? Use your web browser: https://myISPORBaltimore.zerista.com/
entertainment.
Use the same details as used for the myISPORBaltimore web pages. Your ISPOR mobile app
Registration subject to availability. See the ISPOR Registration desk for details.
account email address is the same email address used for your conference registration.
For Social Event Registrants:
Need help? Select “Need help logging in?” on the login screen.
If you have pre-registered for the Social Event, your ticket will print out with your name
Internet/Wi-Fi Sponsored by IQVIA.
badge. You will need this ticket for entry.
Mobile App Sponsored by HealthCore, Inc.
SOCIAL MEDIA
Communicating by way of social media is encouraged if it falls within
REGISTRATION DISCLAIMER
embargo and communications rules.
For security purposes all individuals must be registered and wear the official ISPOR
Be part of the live discussion!
Conference Name Badge to gain access to the conference, the sessions, the exhibit
• Tweet your comments to @ISPORorg during the conference using #ISPORBaltimore
poster hall, and any other ISPOR activity. Onsite staff and security will monitor for name
badges and will deny access if individual does not have an official ISPOR Conference • Access expert insights and share your views on conference sessions at the ISPOR LinkedIn
Name Badge. Individuals not wearing a name badge will be directed to registration. Discussion Group: http://bit.ly/ISPOR-LIn
Please note that if you lose your name badge and need to have it re-printed you cannot • Network with your peers on the ISPOR Facebook page: http://bit.ly/ISPOR-FB
print that at the self-serve station, you will need to visit the registration help desk.
RECORDING & PRESS INFORMATION
Because of the professional nature of the program, safety and liability reasons, guests and
anyone under the age of 18 are not permitted access or to register for the conference. This ISPOR supports the promotion of research presented at ISPOR conferences, while
includes access to the conference in general, to scientific presentations, and to the exhibit and safeguarding sensitive information, data, and research findings that are not yet available to
poster hall. the public. Due to the sensitive nature of data, particularly preliminary unpublished
research findings, all filming and recording of scientific sessions and the poster hall is
For any ISPOR sponsored social event, guests over the age of 21 are permitted to attend but
prohibited during the conference, without the express written consent of ISPOR.
must have a paid event ticket. Due to insurance and liability no one under 21 will be permitted
to attend a social event. Portions of ISPOR 2018 may be recorded by ISPOR. By participating in the discussions,
conference registrants agree that ISPOR may electronically copy, videotape, or audiotape their
LANGUAGE INFORMATION attendance at and involvement in any program. Registration and attendance at ISPOR 2018
All sessions at ISPOR 2018 are presented in English. ISPOR regrets that due to the disruption constitutes an agreement by the registrant to ISPOR’s use and distribution (both now and in
to other delegates, whisper translation (chuchotage) is not permitted in any session, including the future) of their image or voice in photographs, videotapes, electronic reproductions, and
short courses. To discuss options to meet educational needs in multiple languages, please audiotapes of such events and activities. ISPOR will strictly enforce its rights as the exclusive
contact meetingsinfo@ispor.org. licensee of all publication and reproduction rights to each presentation, and no presentation, in
whole or in part, may be reproduced without approval from ISPOR.
COAT CHECK Conference attendees must gain approval from a speaker or poster presenter prior to quoting
You may check your coat, baggage and/or poster with an attendant in the Coat Check Room, or publishing that individual’s scientific results. Members of the press must identify themselves
located on Level 100 of the Baltimore Convention Center. A fee of $3 will be charged for each as such before questioning speakers and congress attendees if using the information in a
item checked. professional capacity.
More detailed information on ISPOR’s Press Pass, Legal, and Embargo Policies are available on
PRESENTATION SLIDES/POSTERS ISPOR’s News & Press page at the ISPOR website (www.ispor.org).
Plenary session, issue panel, workshop, ISPOR forum, and symposia slides will be available For further questions on these policies, please contact: Betsy Lane (blane@ispor.org),
via the conference app and at the ISPOR 2018 Released Presentations page at www.ispor.org Director and Chief Marketing & Communications Officer.
during/after the conference, subject to speaker approval.
Podium and poster presentation abstracts and released slides or poster PDFs are available at the CONFERENCE PROGRAM DISCLAIMER
ISPOR Scientific Presentations Database (a searchable database of over 45,000 research papers Please be advised that while the conference program is designed to provide accurate
presented at ISPOR conferences) at http://www.ispor.org/research_study_digest/index.asp. information regarding the subject matter covered, the views, opinions, and recommendations
The Released Presentations page will feature many of the conference’s slide presentations expressed are those of the authors and speakers, not of ISPOR, and thus ISPOR does not
as PDFs. In 2017, more than 80% of the presentations were available to the public during/ guarantee the accuracy of the information disseminated. If professional advice is desired,
after the conference. The Released Presentations page is accessible via the conference please consult a competent professional.
mobile app and at https://www.ispor.org/Event/index/2018Baltimore.
ANTITRUST COMPLIANCE
SPEAKER INFORMATION It is the undeviating policy of ISPOR to comply strictly with the letter and spirit of all local and
Upload the final version of your slide presentation in the Speaker Ready Room on the U.S. Federal, State, and applicable international trade regulations and antitrust laws. Any
same day of your session! activities of ISPOR or ISPOR-related actions of its officers, Executive Committee Members, or
All speakers are encouraged to use the Speaker Ready Room to preview their slide members that violate these regulations and laws are detrimental to the interests of ISPOR and
presentation and/or upload an updated version. Presentations submitted to ISPOR Speaker’s are unequivocally contrary to ISPOR policy.
Corner by the specified advance deadline and all presentations uploaded/updated in the
FINANCIAL DISCLOSURE INFORMATION
Speaker Ready Room 30 minutes prior to the session will be pre-loaded to the computer in
the session room. All speakers are requested to arrive at their presentation room 15 minutes Research podium and poster presentation financial disclosure information will be available
prior to the session start time. ISPOR staff will be available in the session room to assist the online at: https://www.ispor.org/valueinhealth_index.asp in Value in Health (Volume 21, Suppl 1)
presenter. in June 2018. Faculty and staff involved in the planning or presentation of this conference are
required to disclose all real or apparent commercial financial affiliations related to conference
A speaker ready room is provided in Room 311 (Level 300) with the following opening hours:
content. This information is available on request at the ISPOR Registration desk.
• Sunday, May 20: 12:00PM-6:00PM
• Monday, May 21: 8:00AM-6:00PM QUESTIONS & INFORMATION
• Tuesday, May 22: 8:00AM-6:00PM
Please ask ISPOR staff members for any additional information about the conference or about
• Wednesday, May 23: 8:00AM-3:00PM
ISPOR. ISPOR staff can be identified by their ISPOR name badge.
ISPOR RESEARCH PRESENTATION AWARDS
Awards are given for the best research presentations for podiums and posters in the
categories of GENERAL, NEW INVESTIGATOR, and STUDENT (up to 3 in each category).
www.ispor.org 55
CONWAY STREET
Level 400 FOOD SERVICE/KITCHEN

VIP
WEST
Nursing Conference Rooms

Floor Plan
Mother’s
S
Room
Multi-Faith
Prayer
Room
VIP
EAST BALLROOM II BALLROOM IV
HOWARD STREET
SHARP STREET
CONWAY STREET
BALLROOM I BALLROOM III CAMDEN TERRACE
S CAMDEN LOBBY
Coffee Stations - Networking Areas

Level 300 BALLROOM FOYER S 350 . 349 348 347 346 345
344
E
S 343
PRATT STREET 342

S
HOWARD STREET
341
340
Access to Ballrooms
on 4th level 339
Level 300
306 313 320 323 326 329 332 335 338
303
TERRACE
315 317
CHARLES STREET
305 312 319 322 325 328 331 334 337

302 307 308 309 310 S
314 316 333 336
301 304 311 318 321 324 327 330
Short Courses, Breakout Sessions and Invitational

E
Group Meeting Rooms
AV BUSINESS
Charles F
C
S Terrace S OFFICE CENTER
Market Fresh Cafe S

E Sharp
Option 1 E MAIN TERRACE Terrace EAST WEST
Starbucks
PRATT STREET LOBBY
Network SKYWALK
TERRACE
Starbucks S
Seating to Hilton
Lounges OUTDOOR TERRACE
TERRACE
S S
Level 200 CONWAY STREET

PRATT STREET
E
Skywalk
E
OTTERBEIN LOBBY
S S
Level 200 S
S
E
HOWARD STREET
EXECUTIVE
OFFICES
E
S
BOARD
ROOM
SHARP STREET
SHARP
S S STREET S
LOBBY
E
SKYWALK to S V
S
Inner Harbor E
and Hotels S
CHARLES STREET
CONWAY STREET
Digital S E S
Box Box
Office S S Office
ESC ESC
Health S E S
Showcase PRATT STREET PRATT STREET ENTRANCE

E
F
C
Level 100 ESC

S
E
F
HOWARD STREET
HALL A HALL B
E
Hall A
Drive in Access S
Plenary
#ISPORBaltimore
S
Exhibit
S S
Charles
F
VIP
F E
Poster Hall -
CHARLES STREET
S
CHARLES Lunch and WI-FI NETWORK: ISPOR
SS
Network Seating Areas
STREET
LOBBY
Registration HALL C HALL D

S S
S PASSWORD: IQVIA2018
Coat/ E
Luggage
www.ispor.org
S PRATT STREET S
LOWER LOBBY
Check
PRATT STREET

Ispor 2018 Final Program

Uploaded by

Document Information

Original Description:

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Ispor 2018 Final Program

Uploaded by

Copyright:

Available Formats

ISPOR2018

May 19-23, 2018

Program and Schedule of Events

CONFERENCE PROGRAM COMMITTEE 7

INVITATIONAL GROUP MEETINGS 37

EXHIBIT PROGRAM OVERVIEW 41

EXHIBIT/POSTER HALL FLOOR PLAN 43

2018 ISPOR AWARDS PROGRAM 45

CONFERENCE ROOMS FLOOR PLAN 56

ISPOR 2018 Agenda at a Glance

Sunday, May 20, 2018

Monday, May 21, 2018

Tuesday, May 22, 2018

Wednesday, May 23, 2018

ISPOR Dubai 2018

ISPOR Europe 2018

For more information and to register:

Looking ahead to 2019 Conferences:

Conference Program Committee

PROGRAM COMMITTEE CO-CHAIRS ISSUE PANEL REVIEW COMMITTEE CO-CHAIRS

C. Daniel Mullins, PhD Catherine Tak Piech, MBA

Rachael L. Fleurence, PhD Lotte Steuten, PhD

Ebere Onukwugha, MS, PhD

Marc Berger, PhD

David Vanness, PhD

K. Jack Ishak, PhD

Thank You to Our Sponsors

Platinum Level Sponsors

Gold Level Sponsors

Silver Level Sponsors

Bronze Level Sponsors

FIRST PLENARY SESSION: INFLECTION POINT FOR REAL-WORLD EVIDENCE? THE

SECOND PLENARY SESSION: DIGITAL HEALTH — HELP OR HYPE?

THIRD PLENARY SESSION: EXAMINING THE ROLE OF PATIENT PREFERENCES TO INFORM

WI-FI NETWORK: ISPOR

Looking for presentations from ISPOR 2018?

More than 85% of presentations are expected to be available!

Program & Schedule of Events

● Monday May 21 innovation of interest to the ISPOR community.

8:00AM-5:00PM SHORT COURSE FULL DAY (Separate Registration Required)

8:00AM-12:00PM SHORT COURSE MORNING SESSION (Separate Registration Required)

1:00PM-5:00PM SHORT COURSE AFTERNOON SESSION (Separate Registration Required)

5:30PM-6:30PM EDUCATIONAL SYMPOSIUM Room 309 (Level 300)

< advertisement >

8:00AM-10:00PM EXHIBITOR MOVE IN Halls B-D (Level 100)

8:00AM-12:00PM SHORT COURSE MORNING SESSION (Separate Registration Required)

Indicates hands-on exercises requiring the use of your personal computer.

12:00PM-6:00PM SPEAKER READY ROOM HOURS Room 311 (Level 300)

12:00PM-6:00PM DIGITAL HEALTH SHOWCASE (Level 200)

1:00PM-5:00PM SHORT COURSE AFTERNOON SESSION (Separate Registration Required)

5:30PM-6:30PM EDUCATIONAL SYMPOSIUM Room 309 (Level 300)

6:30PM-8:30PM ISPOR STUDENT RESEARCH COMPETITION Ballroom I (Level 400)

6:45PM-7:45PM EDUCATIONAL SYMPOSIUM Room 309 (Level 300)

8:00AM-6:00PM SPEAKER READY ROOM HOURS Room 311 (Level 300)

8:30AM-7:45PM EXHIBIT/POSTER HALL HOURS Halls B-D (Level 100)

8:30AM-2:00PM RESEARCH POSTER PRESENTATIONS - SESSION I Halls B-D (Level 100)

8:30AM-10:30AM WELCOME & FIRST PLENARY SESSION Hall A (Level 100)

10:30AM-6:00PM DIGITAL HEALTH SHOWCASE (Level 200)

11:00AM-12:00PM BREAKOUT SESSION

P1: Cost-Eﬀectiveness Studies Ballroom IV (Level 400)

11:00AM-12:00PM ISPOR NEW PROFESSIONAL EVENT Room 316-317 (Level 300)

12:30PM-1:30PM EDUCATIONAL SYMPOSIUM Room 309 (Level 300)

12:30PM-1:30PM ISPOR STUDENT RESEARCH SHOWCASE Room 310 (Level 300)